{"bill": {"@star-print": "no-star-print", "#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "@display": "no", "#text": "IN THE SENATE OF THE UNITED\n\t\t  STATES"}, "enrolled-dateline": {"#tail": "\n\t\t", "@display": "yes", "#text": "Begun and held at the City of Washington on Thursday, the third\n\t\tday of January, two thousand and thirteen"}, "congress": {"#tail": "\n\t\t", "#text": "One Hundred Thirteenth Congress of the United States of\n\t\t  America"}, "#tail": "\n\t", "#text": "\n\t\t", "legis-num": {"#tail": "\n\t\t", "@display": "yes", "#text": "S. 622"}, "official-title": {"#tail": "\n\t", "@display": "yes", "#text": "To amend the Federal Food, Drug, and\n\t\t  Cosmetic Act to reauthorize user fee programs relating to new animal drugs and\n\t\t  generic new animal drugs."}, "@display": "yes", "session": {"#tail": "\n    ", "@display": "yes", "#text": "1st Session"}, "legis-type": {"#tail": "\n\t\t", "@display": "yes", "#text": "AN ACT"}}, "attestation": {"#tail": "\n", "attestation-group": [{"#tail": "\n\t\t", "role": {"#tail": "\n\t\t", "#text": "Speaker of the House of Representatives"}, "#text": "\n\t\t\t", "attestor": {"#tail": "\n\t\t\t", "@display": "no"}}, {"#tail": "\n\t", "role": {"#tail": "\n\t\t", "#text": "Vice President of the United States and President of the\n\t\t\t Senate"}, "#text": "\n\t\t\t", "attestor": {"#tail": "\n\t\t\t", "@display": "no"}}], "#text": "\n\t\t"}, "@stage-count": "1", "@bill-stage": "Enrolled-Bill", "@bill-type": "olc", "@public-private": "public", "legis-body": {"@style": "OLC", "title": [{"@level-type": "subsequent", "section": [{"@section-type": "subsequent-section", "#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "101."}, "header": {"#tail": "\n\t\t\t\t", "#text": "Short title; finding", "@display-inline": "yes-display-inline"}, "subsection": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "quote": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "act", "#text": "Animal Drug User Fee Amendments of 2013", "@value": "Animal Drug User Fee Amendments of 2013", "@proposed": "true"}, "#text": "\n              "}, "#text": "This title may be cited as the\n\t\t\t ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(a)"}, "header": {"#tail": "\n          ", "#text": "Short title", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "id4D67D4B50BC5474399DBCD21987163B9", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " finds that the fees authorized by\n\t\t\t the amendments made in this title will be dedicated toward expediting the\n\t\t\t animal drug development process and the review of new and supplemental animal\n\t\t\t drug applications and investigational animal drug submissions as set forth in\n\t\t\t the goals identified, for purposes of ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, {"#tail": ", in the letters from the ", "@entity-type": "act", "#text": "part 4 of subchapter C of chapter VII of\n\t\t\t the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:4"}, {"#tail": " to the ", "@entity-type": "federal-body", "#text": "Secretary of\n\t\t\t Health and Human Services", "@entity-id": "7500"}, {"#tail": " and the ", "@entity-type": "committee", "#text": "Chairman of the Committee on Energy and\n\t\t\t Commerce of the House of Representatives", "@entity-id": "HIF00"}, {"#tail": " as set forth in the\n\t\t\t Congressional Record.", "@entity-type": "committee", "#text": "Chairman of the Committee on\n\t\t\t Health, Education, Labor, and Pensions of the Senate", "@entity-id": "SSHR00"}], "#text": "\n            ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(b)"}, "header": {"#tail": "\n          ", "#text": "Finding", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "idCCB5BB80E2324FCCBA82464242AA3C39", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "idF24B38947FC6403FAF022C0E445C8BB9", "@commented": "no"}, {"@section-type": "subsequent-section", "#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended to read as follows:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 739 of the Federal Food, Drug, and\n\t\t\t Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:739"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u201311", "@entity-type": "uscode", "#text": "21 U.S.C. 379j", "@value": "usc/21/379j"}, "@entity-type": "uscode", "#text": "\n              "}, "@parsable-cite": "usc/21/379j-11", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n        ", "#text": "102."}, "header": {"#tail": "\n        ", "#text": "Definitions", "@display-inline": "yes-display-inline"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "section": {"@section-type": "subsequent-section", "#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "For purposes of this part:", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n            ", "#text": "739."}, "header": {"#tail": "\n            ", "#text": "Definitions", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ". Such term does not include either a new\n\t\t\t\tanimal drug application submitted under ", "@entity-type": "act", "#text": "section 512(b)(1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:512/ss:b/p:1"}, {"#tail": " or a supplemental\n\t\t\t\tanimal drug application.", "@entity-type": "act", "#text": "section 512(b)(2)", "@value": "Federal Food, Drug, and Cosmetic Act/s:512/ss:b/p:2"}], "term": {"#tail": " means an application for approval of any new animal drug\n\t\t\t\tsubmitted under ", "#text": "animal drug\n\t\t\t\tapplication"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id2baecaa2201646fd847452d9d7af16b4", "@commented": "no"}, {"@id": "id75dc24faa3c34c498fbfd7528f195f29", "#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": " means\u2014", "#text": "supplemental animal drug\n\t\t\t\tapplication"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "@display-inline": "no-display-inline", "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to approve a\n\t\t\t\tchange in an animal drug application which has been approved; or", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "a request to the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id8d119fd21c4648d1a326ef814ae2b4b4", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " to approve a\n\t\t\t\tchange to an application approved under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " for which data with\n\t\t\t\trespect to safety or effectiveness are required.", "@entity-type": "act", "#text": "section 512(c)(2)", "@value": "Federal Food, Drug, and Cosmetic Act/s:512/ss:c/p:2"}], "#text": "a request to the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id51e3012b17c1410a992ed6c288462421", "@commented": "no"}], "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "term": {"#tail": "\n\t\t\t\tmeans each specific strength or potency of a particular active ingredient or\n\t\t\t\tingredients in final dosage form marketed by a particular manufacturer or\n\t\t\t\tdistributor, which is uniquely identified by the labeler code and product code\n\t\t\t\tportions of the national drug code, and for which an animal drug application or\n\t\t\t\ta supplemental animal drug application has been approved.", "#text": "animal drug product"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id6a97e76f119640d7b7489daab6a5cb06", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "term": {"#tail": " means a foreign or domestic place of business which is at\n\t\t\t\tone general physical location consisting of one or more buildings all of which\n\t\t\t\tare within 5 miles of each other, at which one or more animal drug products are\n\t\t\t\tmanufactured in final dosage form.", "#text": "animal drug\n\t\t\t\testablishment"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(4)"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id45066d48e5bb4af196d4277a5d52bba1", "@commented": "no"}, {"@id": "ide9601ceef80e4db78d44d5541181cf2b", "#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": " means\u2014", "#text": "investigational animal drug\n\t\t\t\tsubmission"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(5)"}, "@display-inline": "no-display-inline", "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " for a new animal drug intended\n\t\t\t\tto be the subject of an animal drug application or a supplemental animal drug\n\t\t\t\tapplication; or", "@entity-type": "act", "#text": "section 512(j)", "@value": "Federal Food, Drug, and Cosmetic Act/s:512/ss:j"}, "#text": "the filing of a claim for an\n\t\t\t\tinvestigational exemption under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id2edccab7936b46849d1ecbf6ec00a0d1", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to evaluate the safety or effectiveness of an\n\t\t\t\tanimal drug application or supplemental animal drug application in the event of\n\t\t\t\ttheir filing.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "the submission of information for the\n\t\t\t\tpurpose of enabling the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id2752196ae8cb42f28d7d3fb12d4b4533", "@commented": "no"}], "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", or a person who has submitted an investigational animal drug\n\t\t\t\tsubmission that has not been terminated or otherwise rendered inactive by the\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "term": {"#tail": "\n\t\t\t\tmeans either an applicant named in an animal drug application that has not been\n\t\t\t\twithdrawn by the applicant and for which approval has not been withdrawn by the\n\t\t\t\t", "#text": "animal drug sponsor"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(6)"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idab5aa508c9ec4de8ac04cf107a60fd1b", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "term": {"#tail": "\n\t\t\t\tmeans, with respect to an animal drug product, a finished dosage form which is\n\t\t\t\tapproved for administration to an animal without substantial further\n\t\t\t\tmanufacturing. Such term includes animal drug products intended for mixing in\n\t\t\t\tanimal feeds.", "#text": "final dosage form"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(7)"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id59ce977dfbc243cab1f36852f9980932", "@commented": "no"}, {"@id": "id8d7966ae48ef4a6fb99cb5bdb30638fd", "#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t\twith respect to the review of animal drug applications, supplemental animal\n\t\t\t\tdrug applications, and investigational animal drug submissions:", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "term": {"#tail": " means the following activities of the ", "#text": "process for the review of\n\t\t\t\tanimal drug applications"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(8)"}, "@display-inline": "no-display-inline", "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "The activities necessary for the review of\n\t\t\t\tanimal drug applications, supplemental animal drug applications, and\n\t\t\t\tinvestigational animal drug submissions.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id57760b3930c54f8b9873957f96fb72cb", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "The issuance of action letters which\n\t\t\t\tapprove animal drug applications or supplemental animal drug applications or\n\t\t\t\twhich set forth in detail the specific deficiencies in animal drug\n\t\t\t\tapplications, supplemental animal drug applications, or investigational animal\n\t\t\t\tdrug submissions and, where appropriate, the actions necessary to place such\n\t\t\t\tapplications, supplements or submissions in condition for approval.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id0e6dbab31cf54fd2a5ed64fd3059f60b", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t\treview of pending animal drug applications, supplemental animal drug\n\t\t\t\tapplications, and investigational animal drug submissions.", "@entity-type": "federal-body", "#text": "Secretary\u2019s", "@entity-id": "7500"}, "#text": "The inspection of animal drug\n\t\t\t\testablishments and other facilities undertaken as part of the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "ida5ed9b515c064d799b9b1dd5bd635681", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Monitoring of research conducted in\n\t\t\t\tconnection with the review of animal drug applications, supplemental animal\n\t\t\t\tdrug applications, and investigational animal drug submissions.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(D)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id4660e2af831f46c6b5219d1b9b5088a3", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "The development of regulations and policy\n\t\t\t\trelated to the review of animal drug applications, supplemental animal drug\n\t\t\t\tapplications, and investigational animal drug submissions.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(E)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id16c5e7d415c240c39e1a7764e7c8aa43", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Development of standards for products\n\t\t\t\tsubject to review.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(F)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idbca0bdd8d87d4c42987b6660266a124a", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Meetings between the agency and the animal\n\t\t\t\tdrug sponsor.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(G)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idd31eb8de324c4ed98b7d171b426aa0d6", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Review of advertising and labeling prior to\n\t\t\t\tapproval of an animal drug application or supplemental animal drug application,\n\t\t\t\tbut not after such application has been approved.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(H)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id9ec33da95791400882f4a37b4d293a0d", "@commented": "no"}], "@commented": "no"}, {"@id": "id280ae9c17847498cb26aebb44e12376e", "#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": " means the\n\t\t\t\texpenses in connection with the process for the review of animal drug\n\t\t\t\tapplications for\u2014", "#text": "costs of resources allocated\n\t\t\t\tfor the process for the review of animal drug applications"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(9)"}, "@display-inline": "no-display-inline", "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", contractors of the ", "@entity-type": "federal-body", "#text": "Food and Drug\n\t\t\t\tAdministration", "@entity-id": "7524"}, {"#tail": ", advisory\n\t\t\t\tcommittees consulted with respect to the review of specific animal drug\n\t\t\t\tapplications, supplemental animal drug applications, or investigational animal\n\t\t\t\tdrug submissions, and costs related to such officers, employees, committees,\n\t\t\t\tand contractors, including costs for travel, education, and recruitment and\n\t\t\t\tother personnel activities;", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "officers and employees of the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id4a075b710b6a4c508c6b1e88e547b378", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "management of information and the\n\t\t\t\tacquisition, maintenance, and repair of computer resources;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idb8bac221e506493fa513ba7b1b6488cc", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "leasing, maintenance, renovation, and\n\t\t\t\trepair of facilities and acquisition, maintenance, and repair of fixtures,\n\t\t\t\tfurniture, scientific equipment, and other necessary materials and supplies;\n\t\t\t\tand", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id0f945ec9caf748b3a1398c0ece5557e3", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " and\n\t\t\t\taccounting for resources allocated for the review of animal drug applications,\n\t\t\t\tsupplemental animal drug applications, and investigational animal drug\n\t\t\t\tsubmissions.", "@entity-type": "act", "#text": "section 740", "@value": "Federal Food, Drug, and Cosmetic Act/s:740", "@proposed": "true"}, "#text": "collecting fees under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(D)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id33d0d930d7814ff1ab1fa64b560de746", "@commented": "no"}], "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t\twith the base or comparator month being October 2002.", "@entity-type": "act", "#text": "section 735(8)", "@value": "Federal Food, Drug, and Cosmetic Act/s:735/p:8"}, "term": {"#tail": "\n\t\t\t\tapplicable to a fiscal year refers to the formula set forth in ", "#text": "adjustment factor"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(10)"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idda64e305fd5e4f5ba8c1921029ec65db", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "term": {"#tail": " includes an\n\t\t\t\taffiliate thereof.", "#text": "person"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(11)"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idd530b8631d82409d9e199b02bf4b90b9", "@commented": "no"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section\n\t\t\t\t735(11)", "@value": "Federal Food, Drug, and Cosmetic Act/s:735/p:11"}, "term": {"#tail": " refers to\n\t\t\t\tthe definition set forth in ", "#text": "affiliate"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(12)"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "ida520e53d480c419d99108ffc83029fe8", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "id2cfb2137b4f849b28383ff7535ad2157", "@commented": "no"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "id2B676713CF5A43E7A28E98883B5193AF"}, "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "id18C46899033642ECAD36671387E81948", "@commented": "no"}, {"@section-type": "subsequent-section", "#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended to read as\n\t\t\t follows:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 740 of the\n\t\t\t Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:740"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u201312", "@entity-type": "uscode", "#text": "21 U.S.C. 379j", "@value": "usc/21/379j"}, "@entity-type": "uscode", "#text": "\n              "}, "@parsable-cite": "usc/21/379j-12", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n        ", "#text": "103."}, "header": {"#tail": "\n        ", "#text": "Authority to assess and use animal drug\n\t\t\t fees", "@display-inline": "yes-display-inline"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "section": {"@section-type": "subsequent-section", "#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "740."}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Authority to assess and use animal drug\n\t\t\t\tfees", "@display-inline": "yes-display-inline"}, "subsection": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall assess and collect fees in accordance with this section as\n\t\t\t\tfollows:", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Beginning in fiscal year 2004, the\n\t\t\t\t", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(a)"}, "header": {"#tail": "\n              ", "#text": "Types of fees", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "@id": "id856c6a5f331349858672440b4b1afaef", "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Animal drug application and supplement\n\t\t\t\tfee", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "Each person that submits, on or after\n\t\t\t\tSeptember 1, 2003, an animal drug application or a supplemental animal drug\n\t\t\t\tapplication shall be subject to a fee as follows:", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 512(d)(4)", "@value": "Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:4"}, "#text": "A fee established in subsection (c) for an\n\t\t\t\tanimal drug application, except an animal drug application subject to the\n\t\t\t\tcriteria set forth in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "idf3be932ff6c44f0eb559e8781c278625", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t\t", "#text": "A fee established in subsection (c), in an\n\t\t\t\tamount that is equal to 50 percent of the amount of the fee under clause (i),\n\t\t\t\tfor\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "subclause": [{"#tail": "\n                    ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t\t", "#text": "a supplemental animal drug application for\n\t\t\t\twhich safety or effectiveness data are required; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                      ", "#text": "(I)"}, "@display-inline": "no-display-inline", "#text": "\n                      ", "@id": "id71eba9cd8cc9432bb086eae9b19271f1", "@commented": "no"}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 512(d)(4)", "@value": "Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:4"}, "#text": "an animal drug application subject to the\n\t\t\t\tcriteria set forth in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                      ", "#text": "(II)"}, "@display-inline": "no-display-inline", "#text": "\n                      ", "@id": "iddaa6e8cc556745eba9d35e6e6cfdf566", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id0ea29b3247bb47aebd6f6599a5adb1f7", "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id96eff9f07a5842a4a4b1a8d0e987e7f7", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "The fee required by subparagraph (A) shall\n\t\t\t\tbe due upon submission of the animal drug application or supplemental animal\n\t\t\t\tdrug application.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n                  ", "#text": "Payment", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idad0ccb7a9ce2485e856a3962aa83a00b", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "If an animal\n\t\t\t\tdrug application or a supplemental animal drug application was submitted by a\n\t\t\t\tperson that paid the fee for such application or supplement, was accepted for\n\t\t\t\tfiling, and was not approved or was withdrawn (without a waiver or refund), the\n\t\t\t\tsubmission of an animal drug application or a supplemental animal drug\n\t\t\t\tapplication for the same product by the same person (or the person\u2019s licensee,\n\t\t\t\tassignee, or successor) shall not be subject to a fee under subparagraph\n\t\t\t\t(A).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "header": {"#tail": "\n                  ", "#text": "Exception for previously filed application\n\t\t\t\tor supplement", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id00381df24dbb4c6fa9672051607e83ff", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\n\t\t\t\trefund 75 percent of the fee paid under subparagraph (B) for any animal drug\n\t\t\t\tapplication or supplemental animal drug application which is refused for\n\t\t\t\tfiling.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "header": {"#tail": "\n                  ", "#text": "Refund of fee if application refused for\n\t\t\t\tfiling", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id1fb0e71de8754f73b85f71fbdeec1d3a", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may refund the fee or\n\t\t\t\tportion of the fee paid under subparagraph (B) if no substantial work was\n\t\t\t\tperformed on the application or supplement after the application or supplement\n\t\t\t\twas filed. The ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall have the sole discretion to refund the fee under\n\t\t\t\tthis paragraph. A determination by the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " concerning a refund under this\n\t\t\t\tparagraph shall not be reviewable.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "If an animal drug\n\t\t\t\tapplication or a supplemental animal drug application is withdrawn after the\n\t\t\t\tapplication or supplement was filed, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(E)"}, "header": {"#tail": "\n                  ", "#text": "Refund of fee if application\n\t\t\t\twithdrawn", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "ida24a0748809b462995e81936d8d6a70c", "@commented": "no"}], "@commented": "no"}, {"#tail": "\n              ", "@id": "idd244aeb1ac2344d6963dbdab2111e2ec", "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Animal drug product fee", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "subparagraph": [{"continuation-text": {"#tail": "\n                ", "@continuation-text-level": "subparagraph", "#text": "shall pay for each such animal\n\t\t\t\tdrug product the annual fee established in subsection (c).", "@commented": "no"}, "#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "Each person\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; and", "@entity-type": "act", "#text": "section 510", "@value": "Federal Food, Drug, and Cosmetic Act/s:510"}, "#text": "who is named as the applicant in an animal\n\t\t\t\tdrug application or supplemental animal drug application for an animal drug\n\t\t\t\tproduct which has been submitted for listing under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "idBC3298020FB0493AA055F3DCBFD9368F", "@commented": "no"}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " an animal drug application or supplemental animal drug\n\t\t\t\tapplication,", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "who, after September 1, 2003, had pending\n\t\t\t\tbefore the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id05148E5A0284418DA64B1C1692C81E56", "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "ida938326684b7416ab2de970e84282893", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", or is submitted for relisting under ", "@entity-type": "act", "#text": "section 510", "@value": "Federal Food, Drug, and Cosmetic Act/s:510"}, {"#tail": " if the animal drug\n\t\t\t\tproduct has been withdrawn from listing and relisted. After such fee is paid\n\t\t\t\tfor that fiscal year, such fee shall be due each subsequent fiscal year that\n\t\t\t\tthe product remains listed, upon the later of\u2014", "@entity-type": "act", "#text": "section 510", "@value": "Federal Food, Drug, and Cosmetic Act/s:510"}], "#text": "Such fee shall be payable for the fiscal\n\t\t\t\tyear in which the animal drug product is first submitted for listing under\n\t\t\t\t", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the first business day after the date of\n\t\t\t\tenactment of an appropriations Act providing for the collection and obligation\n\t\t\t\tof fees for such fiscal year under this section; or", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id2a6ea392d4da47048129573d63242b2b", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "January 31 of each year.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "idb2ec0ea5d79140838a1d2f511c1e3dc7", "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "Payment; fee due date", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id286d4e36fdf44cd9bc435819a7fbd697", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Such fee shall be paid only once for each\n\t\t\t\tanimal drug product for a fiscal year in which the fee is payable.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "header": {"#tail": "\n                  ", "#text": "Limitation", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id2c4425400aea4a6b88a4e752b3c37385", "@commented": "no"}], "@commented": "no"}, {"#tail": "\n              ", "@id": "idec70ef13a7d74d6ba337a08e294490a4", "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Animal drug establishment fee", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "subparagraph": [{"continuation-text": {"#tail": "\n                ", "@continuation-text-level": "subparagraph", "#text": "shall be assessed an annual\n\t\t\t\testablishment fee as established in subsection (c) for each animal drug\n\t\t\t\testablishment listed in its approved animal drug application as an\n\t\t\t\testablishment that manufactures the animal drug product named in the\n\t\t\t\tapplication.", "@commented": "no"}, "#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "Each person\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "who owns or operates, directly or through\n\t\t\t\tan affiliate, an animal drug establishment;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id4acd4cf9864a448a847fa0d313f4f3a3", "@commented": "no"}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; and", "@entity-type": "act", "#text": "section 510", "@value": "Federal Food, Drug, and Cosmetic Act/s:510"}, "#text": "who is named as the applicant in an animal\n\t\t\t\tdrug application or supplemental animal drug application for an animal drug\n\t\t\t\tproduct which has been submitted for listing under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id642d0b026cdc4f2bbe966b32014f852e", "@commented": "no"}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " an animal drug application or supplemental animal drug\n\t\t\t\tapplication,", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "who, after September 1, 2003, had pending\n\t\t\t\tbefore the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(iii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id9c7fb6e0216b4ece94ac63dfe6413f60", "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id010c49a9657a4137bd22196c97c59427", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "The annual establishment fee shall be\n\t\t\t\tassessed in each fiscal year in which the animal drug product named in the\n\t\t\t\tapplication is assessed a fee under paragraph (2) unless the animal drug\n\t\t\t\testablishment listed in the application does not engage in the manufacture of\n\t\t\t\tthe animal drug product during the fiscal year. The fee under this paragraph\n\t\t\t\tfor a fiscal year shall be due upon the later of\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the first business day after the date of\n\t\t\t\tenactment of an appropriations Act providing for the collection and obligation\n\t\t\t\tof fees for such fiscal year under this section; or", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id6c8e2638580f4fecab2326fb11e275e1", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "January 31 of each year.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id8288061bb7b24630b96cd9f96dad6f2e", "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "Payment; fee due date", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id3f9baeb57de64faf8d8657f94716b49e", "@commented": "no"}, {"#tail": "\n              ", "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "An establishment shall be assessed only one\n\t\t\t\tfee per fiscal year under this section, subject to clause (ii).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "header": {"#tail": "\n                    ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id85654F3F1AD54EE7BCE665138E7EBF7A", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", such establishment shall be assessed both the animal drug establishment\n\t\t\t\tfee and the prescription drug establishment fee, as set forth in ", "@entity-type": "act", "#text": "section\n\t\t\t\t735(3)", "@value": "Federal Food, Drug, and Cosmetic Act/s:735/p:3"}, {"#tail": ", within a single fiscal year.", "@entity-type": "act", "#text": "section\n\t\t\t\t736(a)(2)", "@value": "Federal Food, Drug, and Cosmetic Act/s:736/ss:a/p:2"}], "#text": "If a single establishment manufactures both\n\t\t\t\tanimal drug products and prescription drug products, as defined in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "header": {"#tail": "\n                    ", "#text": "Certain manufacturers", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id4C9A24E9FF104B879A9F8E585E05E10A", "@commented": "no"}], "enum": {"#tail": "\n                  ", "#text": "(C)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "Limitation", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id1ca0cb6f97034855983c73b83030b397", "@commented": "no"}], "@commented": "no"}, {"#tail": "\n            ", "@id": "id5e99b2cdcba34a879d151c9d44a84bb1", "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Animal drug sponsor fee", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "subparagraph": [{"continuation-text": {"#tail": "\n                ", "@continuation-text-level": "subparagraph", "#text": "shall be assessed an annual\n\t\t\t\tsponsor fee as established under subsection (c).", "@commented": "no"}, "#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "Each person\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "who meets the definition of an animal drug\n\t\t\t\tsponsor within a fiscal year; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id4713777554EA4736B68AE28C4A83A989", "@commented": "no"}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " an animal drug application, a supplemental animal drug\n\t\t\t\tapplication, or an investigational animal drug submission,", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "who, after September 1, 2003, had pending\n\t\t\t\tbefore the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id75DDE84866DB44BCA26229F56E7666E2", "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idc86ef39ce2f34dd3a7ce643d12eba1a6", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "The fee under this paragraph for a fiscal\n\t\t\t\tyear shall be due upon the later of\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the first business day after the date of\n\t\t\t\tenactment of an appropriations Act providing for the collection and obligation\n\t\t\t\tof fees for such fiscal year under this section; or", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id7e4068f8a77841669b9f09685ef74e6e", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "January 31 of each year.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "iddb992fd0b12f410fb9360a188d36568c", "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "Payment; fee due date", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id9bbd59ab18014db9917df43009811793", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Each animal drug sponsor shall pay only one\n\t\t\t\tsuch fee each fiscal year.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "header": {"#tail": "\n                  ", "#text": "Limitation", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idf247453a92744a588729e8746796c011", "@commented": "no"}], "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id2dc2344c349f4586842f585b9e903b2a", "@commented": "no"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(b)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Fee revenue amounts", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Subject to subsections (c), (d), (f), and\n\t\t\t\t(g)\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idc6f6d9a0f4fb4101bf6de214b0d82488", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "for fiscal year 2014, the fees required\n\t\t\t\tunder subsection (a) shall be established to generate a total revenue amount of\n\t\t\t\t$23,600,000; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id6a536a7f69564371933dc08c908acabf", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "for each of fiscal years 2015 through 2018,\n\t\t\t\tthe fees required under subsection (a) shall be established to generate a total\n\t\t\t\trevenue amount of $21,600,000.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idb13cfed06f6e4e7aa99336a2bf060685", "@commented": "no"}]}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Of the total revenue amount determined for\n\t\t\t\ta fiscal year under paragraph (1)\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Types of fees", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idee0a35c16b3a4f43ad07525becf7368b", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "20 percent shall be derived from fees under\n\t\t\t\tsubsection (a)(1) (relating to animal drug applications and\n\t\t\t\tsupplements);", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idcba4797710da4bcf9dac068921f3f593", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "27 percent shall be derived from fees under\n\t\t\t\tsubsection (a)(2) (relating to animal drug products);", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "ide8c86e8cc8f744a99e582ad1290ed7eb", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "26 percent shall be derived from fees under\n\t\t\t\tsubsection (a)(3) (relating to animal drug establishments); and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id85513e950b0c458eb546e8af614947ef", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "27 percent shall be derived from fees under\n\t\t\t\tsubsection (a)(4) (relating to animal drug sponsors).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id3cd66be54caf46099e22401bebd73de5", "@commented": "no"}]}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idaf35bbefbdb747f09941f1977c0d1bdc", "@commented": "no"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(c)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Annual fee setting; adjustments", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall establish, 60 days\n\t\t\t\tbefore the start of each fiscal year beginning after September 30, 2003, for\n\t\t\t\tthat fiscal year, animal drug application fees, supplemental animal drug\n\t\t\t\tapplication fees, animal drug sponsor fees, animal drug establishment fees, and\n\t\t\t\tanimal drug product fees based on the revenue amounts established under\n\t\t\t\tsubsection (b) and the adjustments provided under this subsection.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Annual fee setting", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id1be44308ec41422c91c09183f6d5a32f", "@commented": "no"}, {"continuation-text": {"#tail": "\n              ", "@continuation-text-level": "paragraph", "#text": "The adjustment made each fiscal year\n\t\t\t\tunder this paragraph shall be added on a compounded basis to the sum of all\n\t\t\t\tadjustments made each fiscal year after fiscal year 2014 under this\n\t\t\t\tparagraph.", "@commented": "no"}, "#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " by notice, published in the Federal Register, for a fiscal year,\n\t\t\t\tby an amount equal to the sum of\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "For fiscal year 2015 and subsequent fiscal\n\t\t\t\tyears, the revenue amounts established in subsection (b) shall be adjusted by\n\t\t\t\tthe ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Inflation adjustment", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idab2a98ea0a174a14b3c19e52ec354a1f", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "one;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id11ecb2d82c084e5b85946436249a2b58", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", of\n\t\t\t\tall personnel compensation and benefits paid with respect to such positions for\n\t\t\t\tthe first 3 of the preceding 4 fiscal years for which data are available,\n\t\t\t\tmultiplied by the average proportion of personnel compensation and benefits\n\t\t\t\tcosts to total ", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, {"#tail": " costs for the first 3 years of the\n\t\t\t\tpreceding 4 fiscal years for which data are available; and", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "the average annual percent change in the\n\t\t\t\tcost, per full-time equivalent position of the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id45520518539845659230174a4d7e3886", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t\tcosts for the first 3 years of the preceding 4 fiscal years for which data are\n\t\t\t\tavailable.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "#text": "the average annual percent change that\n\t\t\t\toccurred in the Consumer Price Index for urban consumers (Washington-Baltimore,\n\t\t\t\tDC\u2013MD\u2013VA\u2013WV; not seasonally adjusted; all items less food and energy; annual\n\t\t\t\tindex) for the first 3 years of the preceding 4 years for which data are\n\t\t\t\tavailable multiplied by the average proportion of all costs other than\n\t\t\t\tpersonnel compensation and benefits costs to total ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "ide1111c4d711a4bc0b60c7bdf4ef39252", "@commented": "no"}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " for the process for the review of animal drug applications. With\n\t\t\t\trespect to such adjustment\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "For fiscal year 2015 and subsequent fiscal\n\t\t\t\tyears, after the revenue amounts established in subsection (b) are adjusted for\n\t\t\t\tinflation in accordance with paragraph (2), the revenue amounts shall be\n\t\t\t\tfurther adjusted for such fiscal year to reflect changes in the workload of the\n\t\t\t\t", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Workload adjustment", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "ida926d9804abd48fa97bb5eafb148e7d3", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " based on a weighted average of the change in the total number of\n\t\t\t\tanimal drug applications, supplemental animal drug applications for which data\n\t\t\t\twith respect to safety or effectiveness are required, manufacturing\n\t\t\t\tsupplemental animal drug applications, investigational animal drug study\n\t\t\t\tsubmissions, and investigational animal drug protocol submissions submitted to\n\t\t\t\tthe ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ";", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "such adjustment shall be determined by the\n\t\t\t\t", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id8cf934fc86e7475cb281bedfcfde33c6", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall publish in the Federal\n\t\t\t\tRegister the fees resulting from such adjustment and the supporting\n\t\t\t\tmethodologies; and", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idA23B3BFEEFD947EDB19E5DF7AE6AB4DF", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "under no circumstances shall such\n\t\t\t\tadjustment result in fee revenues for a fiscal year that are less than the fee\n\t\t\t\trevenues for that fiscal year established in subsection (b), as adjusted for\n\t\t\t\tinflation under paragraph (2).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id241d33caa9aa4458a1ffefc8dde96f73", "@commented": "no"}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may, in\n\t\t\t\taddition to other adjustments under this subsection, further increase the fees\n\t\t\t\tunder this section, if such an adjustment is necessary, to provide for up to 3\n\t\t\t\tmonths of operating reserves of carryover user fees for the process for the\n\t\t\t\treview of animal drug applications for the first 3 months of fiscal year 2019.\n\t\t\t\tIf the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " has carryover balances for the process for\n\t\t\t\tthe review of animal drug applications in excess of 3 months of such operating\n\t\t\t\treserves, then this adjustment will not be made. If this adjustment is\n\t\t\t\tnecessary, then the rationale for the amount of the increase shall be contained\n\t\t\t\tin the annual notice setting fees for fiscal year 2018.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "For fiscal year 2018, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n                ", "#text": "Final year adjustment", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id22d236418f804be3a2a7dec79c87d001", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "The total amount of fees charged, as\n\t\t\t\tadjusted under this subsection, for a fiscal year may not exceed the total\n\t\t\t\tcosts for such fiscal year for the resources allocated for the process for the\n\t\t\t\treview of animal drug applications.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(5)"}, "header": {"#tail": "\n                ", "#text": "Limit", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id41001dd940b1473fb08295986f21c6a6", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id1a1c4f8297ca4fa5adf7d7ad041d4c12", "@commented": "no"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(d)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Fee waiver or reduction", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall grant a waiver from or\n\t\t\t\ta reduction of one or more fees assessed under subsection (a) where the\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " finds that\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idaca03700b2a3458da373e43ed7ee6165", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "the assessment of the fee would present a\n\t\t\t\tsignificant barrier to innovation because of limited resources available to\n\t\t\t\tsuch person or other circumstances;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id0605974517334d95abb436828ad5217f", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " in\n\t\t\t\tconducting the process for the review of animal drug applications for such\n\t\t\t\tperson;", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "the fees to be paid by such person will\n\t\t\t\texceed the anticipated present and future costs incurred by the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id748e3a4b940b4602a7fed665a4d4d2f9", "@commented": "no"}, {"@display-inline": "no-display-inline", "#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the animal drug application or supplemental\n\t\t\t\tanimal drug application is intended solely to provide for use of the animal\n\t\t\t\tdrug in\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "a Type B medicated feed (as defined in\n\t\t\t\t", "external-xref": {"#tail": " of title 21, Code of Federal Regulations (or any successor\n\t\t\t\tregulation)) intended for use in the manufacture of Type C free-choice\n\t\t\t\tmedicated feeds; or", "@parsable-cite": "cfr/21/558.3", "#text": "section 558.3(b)(3)", "@legal-doc": "regulation"}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "ide819f3de5b8445eebfd87cb6df3ffdfb", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "a Type C free-choice medicated feed (as\n\t\t\t\tdefined in ", "external-xref": {"#tail": " of title 21, Code of Federal Regulations (or any\n\t\t\t\tsuccessor regulation));", "@parsable-cite": "cfr/21/558.3", "#text": "section 558.3(b)(4)", "@legal-doc": "regulation"}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "ida97a890bfb924c4f97282e53e50429be", "@commented": "no"}], "#text": "\n                  ", "@id": "id0888a19d88004833bc3af69869fd5f22", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "the animal drug application or supplemental\n\t\t\t\tanimal drug application is intended solely to provide for a minor use or minor\n\t\t\t\tspecies indication; or", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id54867149a9004d5fa36e326209f80ad0", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " for\n\t\t\t\treview.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "the sponsor involved is a small business\n\t\t\t\tsubmitting its first animal drug application to the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(E)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id27ee5fb886bf42fdb513d26ac1754466", "@commented": "no"}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " may use standard costs.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "In making the finding in paragraph (1)(B),\n\t\t\t\tthe ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Use of standard costs", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idf1216e118c0a48c2941625019319b283", "@commented": "no"}, {"#tail": "\n            ", "@id": "idac78667703e048a2a2b309c08878a132", "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Rules for small businesses", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "term": {"#tail": " means an entity that has fewer than 500 employees, including\n\t\t\t\temployees of affiliates.", "#text": "small\n\t\t\t\tbusiness"}, "#text": "In paragraph (1)(E), the term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "header": {"#tail": "\n                  ", "#text": "Definition", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id63490f3311f24674a2a20d163fa01089", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall waive under paragraph\n\t\t\t\t(1)(E) the application fee for the first animal drug application that a small\n\t\t\t\tbusiness or its affiliate submits to the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " for review. After a small\n\t\t\t\tbusiness or its affiliate is granted such a waiver, the small business or its\n\t\t\t\taffiliate shall pay application fees for all subsequent animal drug\n\t\t\t\tapplications and supplemental animal drug applications for which safety or\n\t\t\t\teffectiveness data are required in the same manner as an entity that does not\n\t\t\t\tqualify as a small business.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n                  ", "#text": "Waiver of application fee", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id8389047c675f4977af7588406623de9b", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall require any person who\n\t\t\t\tapplies for a waiver under paragraph (1)(E) to certify their qualification for\n\t\t\t\tthe waiver. The ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall periodically publish in the Federal Register a\n\t\t\t\tlist of persons making such certifications.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "header": {"#tail": "\n                  ", "#text": "Certification", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "ide87ea137ffb94c83ba6358425b8ae68b", "@commented": "no"}], "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id5f5654bf3e724bb5ad446f03903c5dad", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " until all fees owed by such person have been paid. An investigational\n\t\t\t\tanimal drug submission under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " that is submitted by a person\n\t\t\t\tsubject to fees under subsection (a) shall be considered incomplete and shall\n\t\t\t\tnot be accepted for review by the ", "@entity-type": "act", "#text": "section 739(5)(B)", "@value": "Federal Food, Drug, and Cosmetic Act/s:739/p:5/sp:B", "@proposed": "true"}, {"#tail": " until all fees owed by such person\n\t\t\t\thave been paid. The ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may discontinue review of any animal drug\n\t\t\t\tapplication, supplemental animal drug application or investigational animal\n\t\t\t\tdrug submission from a person if such person has not submitted for payment all\n\t\t\t\tfees owed under this section by 30 days after the date upon which they are\n\t\t\t\tdue.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "An animal drug application or supplemental\n\t\t\t\tanimal drug application submitted by a person subject to fees under subsection\n\t\t\t\t(a) shall be considered incomplete and shall not be accepted for filing by the\n\t\t\t\t", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(e)"}, "header": {"#tail": "\n              ", "#text": "Effect of failure To pay fees", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "ide7cd2c8d294d4fc3ae7c308c5a04b6f2", "@commented": "no"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(f)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Assessment of fees", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " for such fiscal\n\t\t\t\tyear (excluding the amount of fees appropriated for such fiscal year) are equal\n\t\t\t\tto or greater than the amount of appropriations for the salaries and expenses\n\t\t\t\tof the ", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, {"#tail": " for the fiscal year 2003 (excluding the\n\t\t\t\tamount of fees appropriated for such fiscal year) multiplied by the adjustment\n\t\t\t\tfactor applicable to the fiscal year involved.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "Fees may not be assessed under subsection\n\t\t\t\t(a) for a fiscal year beginning after fiscal year 2003 unless appropriations\n\t\t\t\tfor salaries and expenses of the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Limitation", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id8097173620504c51b2377b93e98f8166", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " does not assess fees under\n\t\t\t\tsubsection (a) during any portion of a fiscal year because of paragraph (1) and\n\t\t\t\tif at a later date in such fiscal year the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may assess such fees, the\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may assess and collect such fees, without any modification in the\n\t\t\t\trate, for animal drug applications, supplemental animal drug applications,\n\t\t\t\tinvestigational animal drug submissions, animal drug sponsors, animal drug\n\t\t\t\testablishments and animal drug products at any time in such fiscal year\n\t\t\t\tnotwithstanding the provisions of subsection (a) relating to the date fees are\n\t\t\t\tto be paid.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "If the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Authority", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "ide7984a1f0bf44d048c6f6fc03396fa82", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id65edffaa16784560a40ead49845e81e5", "@commented": "no"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(g)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Crediting and availability of fees", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " salaries and expenses appropriation account without fiscal\n\t\t\t\tyear limitation to such appropriation account for salary and expenses with such\n\t\t\t\tfiscal year limitation. The sums transferred shall be available solely for the\n\t\t\t\tprocess for the review of animal drug applications.", "@entity-type": "federal-body", "#text": "Food and\n\t\t\t\tDrug Administration", "@entity-id": "7524"}, "#text": "Subject to paragraph (2)(C), fees\n\t\t\t\tauthorized under subsection (a) shall be collected and available for obligation\n\t\t\t\tonly to the extent and in the amount provided in advance in appropriations\n\t\t\t\tActs. Such fees are authorized to be appropriated to remain available until\n\t\t\t\texpended. Such sums as may be necessary may be transferred from the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id69eefe8b0407495781fe5652401c79d4", "@commented": "no"}, {"#tail": "\n              ", "@id": "id9f693160d00841d9812c3b60ddd7ac5f", "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Collections and appropriation acts", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "The fees authorized by this section\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "subject to subparagraph (C), shall be\n\t\t\t\tcollected and available in each fiscal year in an amount not to exceed the\n\t\t\t\tamount specified in appropriation Acts, or otherwise made available for\n\t\t\t\tobligation for such fiscal year, and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id06bada831ef44b2b83d2b209e2b20282", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to be engaged in such process) over such costs, excluding costs paid\n\t\t\t\tfrom fees collected under this section, for fiscal year 2003 multiplied by the\n\t\t\t\tadjustment factor.", "@entity-type": "federal-body", "#text": "Department of Health and Human\n\t\t\t\tServices", "@entity-id": "7500"}, "#text": "shall be available to defray increases in\n\t\t\t\tthe costs of the resources allocated for the process for the review of animal\n\t\t\t\tdrug applications (including increases in such costs for an additional number\n\t\t\t\tof full-time equivalent positions in the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id46588b6b48e84a3f83c15e128c4fd3b2", "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id1e7f16bd4e9244d19b3f9d9a1b05c393", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall be considered to have\n\t\t\t\tmet the requirements of subparagraph (A)(ii) in any fiscal year if the costs\n\t\t\t\tfunded by appropriations and allocated for the process for the review of animal\n\t\t\t\tdrug applications\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "are not more than 3 percent below the level\n\t\t\t\tspecified in subparagraph (A)(ii); or", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id403d638ecdd940a8b4b5df219a49f2c2", "@commented": "no"}, {"#tail": "\n                ", "@id": "id5d49f7d3dd7949dabc7af64aa5601d38", "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "subclause": [{"#tail": "\n                    ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t\t", "#text": "are more than 3 percent below the level\n\t\t\t\tspecified in subparagraph (A)(ii), and fees assessed for the fiscal year\n\t\t\t\tfollowing the subsequent fiscal year are decreased by the amount in excess of 3\n\t\t\t\tpercent by which such costs fell below the level specified in subparagraph\n\t\t\t\t(A)(ii); and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                      ", "#text": "(I)"}, "@display-inline": "yes-display-inline", "#text": "\n                      ", "@id": "id843D35BAAB274BAFB62E986A7096C7C2", "@commented": "no"}, {"@indent": "up1", "#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t\t", "#text": "such costs are not more than 5 percent\n\t\t\t\tbelow the level specified in subparagraph (A)(ii).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                      ", "#text": "(II)"}, "@display-inline": "no-display-inline", "#text": "\n                      ", "@id": "idB5FA6A04D5DF454B997DB044F9DFCE62", "@commented": "no"}], "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "Compliance", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id392449b0361a4c37b7b53aad1ef92fcb", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " in accordance with authority provided in advance in a prior\n\t\t\t\tyear appropriations Act.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Payment of fees authorized under this\n\t\t\t\tsection for a fiscal year, prior to the due date for such fees, may be accepted\n\t\t\t\tby the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "header": {"#tail": "\n                  ", "#text": "Provision for early payments", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id31dff28713af4d34bad74c8d4bee74b4", "@commented": "no"}], "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "\n                  ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n                ", "@entity-type": "auth-auth-approp", "#text": "\n                    ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": " ", "#text": "For each of\n\t\t\t\tthe fiscal years 2014 through 2018, there is authorized to be appropriated", "@amount": "indefinite", "@year": "2014, 2015, 2016, 2017, 2018"}, "{http://namespaces.cato.org/catoxml}property": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " for the fiscal year, as adjusted or otherwise affected\n\t\t\t\tunder ", "@entity-type": "act", "#text": "subsection (b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:740/ss:b", "@proposed": "true"}, {"#tail": " and ", "@entity-type": "act", "#text": "subsection (c)", "@value": "Federal Food, Drug, and Cosmetic Act/s:740/ss:c", "@proposed": "true"}, {"#tail": "\n                    ", "@entity-type": "act", "#text": "paragraph (4)", "@value": "Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:4", "@proposed": "true"}], "#text": "for\n\t\t\t\tfees under this section an amount equal to the total revenue amount determined\n\t\t\t\tunder ", "@name": "purpose"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "\n                  Authorization of\n\t\t\t\tappropriations\n                ", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id9edc07c1ec99401386901a6f38345481", "@commented": "no"}, {"#tail": "\n            ", "@id": "idccfd5c44eb3448a68c4d6e6b4c9dd806", "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Offset of overcollections; recovery of\n\t\t\t\tcollection shortfalls", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " as provided in\n\t\t\t\tparagraph (1), and shall be subtracted from the amount of fees that would\n\t\t\t\totherwise be authorized to be collected under this section pursuant to\n\t\t\t\tappropriation Acts for fiscal year 2018.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "#text": "If the sum of the cumulative amount of fees\n\t\t\t\tcollected under this section for fiscal years 2014 through 2016 and the amount\n\t\t\t\tof fees estimated to be collected under this section for fiscal year 2017\n\t\t\t\t(including any increased fee collections attributable to subparagraph (B)),\n\t\t\t\texceeds the cumulative amount appropriated pursuant to paragraph (3) for the\n\t\t\t\tfiscal years 2014 through 2017, the excess amount shall be credited to the\n\t\t\t\tappropriation account of the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "header": {"#tail": "\n                  ", "#text": "Offset of overcollections", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id184e5d32ed594ca0bf3ffd409d100a1c", "@commented": "no"}, {"#tail": "\n              ", "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "For fiscal year 2016, the amount of fees\n\t\t\t\totherwise authorized to be collected under this section shall be increased by\n\t\t\t\tthe amount, if any, by which the amount collected under this section and\n\t\t\t\tappropriated for fiscal year 2014 falls below the amount of fees authorized for\n\t\t\t\tfiscal year 2014 under paragraph (3).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "header": {"#tail": "\n                    ", "#text": "Fiscal year 2016", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id104c67d7fb734180b2c3e8a8b1a865b4", "@commented": "no"}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "For fiscal year 2017, the amount of fees\n\t\t\t\totherwise authorized to be collected under this section shall be increased by\n\t\t\t\tthe amount, if any, by which the amount collected under this section and\n\t\t\t\tappropriated for fiscal year 2015 falls below the amount of fees authorized for\n\t\t\t\tfiscal year 2015 under paragraph (3).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "header": {"#tail": "\n                    ", "#text": "Fiscal year 2017", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id734261ab2af44cfe94750df06bcd059a", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "For fiscal year 2018, the amount of fees\n\t\t\t\totherwise authorized to be collected under this section (including any\n\t\t\t\treduction in the authorized amount under subparagraph (A)), shall be increased\n\t\t\t\tby the cumulative amount, if any, by which the amount collected under this\n\t\t\t\tsection and appropriated for fiscal years 2016 and 2017 (including estimated\n\t\t\t\tcollections for fiscal year 2017) falls below the cumulative amount of fees\n\t\t\t\tauthorized under paragraph (3) for fiscal years 2016 and 2017.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(iii)"}, "header": {"#tail": "\n                    ", "#text": "Fiscal year 2018", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "idcce94146ddcd49a68e7c0fff8fff7738", "@commented": "no"}], "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "Recovery of collection shortfalls", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id59f70c4eda2b48a990d9c7b9ac351e11", "@commented": "no"}], "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id26b0ce484bc3479abb5a8698156becd0", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " does not\n\t\t\t\treceive payment of a fee assessed under subsection (a) within 30 days after it\n\t\t\t\tis due, such fee shall be treated as a claim of the United States Government\n\t\t\t\tsubject to ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "uscode", "#text": "subchapter II of ", "external-xref": {"#tail": " of title 31, United States Code", "@parsable-cite": "usc-chapter/31/37", "#text": "chapter 37", "@legal-doc": "usc-chapter"}, "@value": "usc-chapter/31/37/II"}], "#text": "In any case where the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(h)"}, "header": {"#tail": "\n              ", "#text": "Collection of unpaid fees", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idc76efd22b8394a63903cc6e58714edf1", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " a written request for such waiver, reduction, or refund not\n\t\t\t\tlater than 180 days after such fee is due.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "To qualify for\n\t\t\t\tconsideration for a waiver or reduction under subsection (d), or for a refund\n\t\t\t\tof any fee collected in accordance with subsection (a), a person shall submit\n\t\t\t\tto the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(i)"}, "header": {"#tail": "\n              ", "#text": "Written requests for waivers, reductions,\n\t\t\t\tand refunds", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idda35a235af3e4f8f9c8d98427c724d62", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", for officers, employees, and advisory committees not\n\t\t\t\tengaged in the process of the review of animal drug applications, be reduced to\n\t\t\t\toffset the number of officers, employees, and advisory committees so\n\t\t\t\tengaged.", "@entity-type": "federal-body", "#text": "Department of\n\t\t\t\tHealth and Human Services", "@entity-id": "7500"}, "#text": "This section may not be construed to\n\t\t\t\trequire that the number of full-time equivalent positions in the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(j)"}, "header": {"#tail": "\n              ", "#text": "Construction", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id711bcda79b1640eda8809e41b0caa566", "@commented": "no"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t\tshall\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(k)"}, "header": {"#tail": "\n              ", "#text": "Abbreviated new animal drug\n\t\t\t\tapplications", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "to the extent practicable, segregate the\n\t\t\t\treview of abbreviated new animal drug applications from the process for the\n\t\t\t\treview of animal drug applications; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id33baecf53cf54a36b38df809eb9926cb", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "adopt other administrative procedures to\n\t\t\t\tensure that review times of abbreviated new animal drug applications do not\n\t\t\t\tincrease from their current level due to activities under the user fee\n\t\t\t\tprogram.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idfcf2953d5595412b81d55a821bdc4cf6", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id16bb5dd7abb14d298f632d69081702f3", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "id20bd7243cd6d4ec0bde67d3531977f61", "@commented": "no"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "idE6F90BE0E0A74214B31A51B5B1004BEC"}, "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "idE57FA6A8996142F597DE8AD3F7810778", "@commented": "no"}, {"@section-type": "subsequent-section", "#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended to read\n\t\t\t as follows:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 740A of\n\t\t\t the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:740A"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u201313", "@entity-type": "uscode", "#text": "21 U.S.C. 379j", "@value": "usc/21/379j"}, "@entity-type": "uscode", "#text": "\n              "}, "@parsable-cite": "usc/21/379j-13", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n        ", "#text": "104."}, "header": {"#tail": "\n        ", "#text": "Reauthorization; reporting\n\t\t\t requirements", "@display-inline": "yes-display-inline"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "section": {"@section-type": "subsequent-section", "#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "740A."}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Reauthorization; reporting\n\t\t\t\trequirements", "@display-inline": "yes-display-inline"}, "subsection": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall prepare and submit to the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and the ", "@entity-type": "committee", "#text": "Committee on\n\t\t\t\tHealth, Education, Labor, and Pensions of the Senate", "@entity-id": "SSHR00"}, {"#tail": " a report concerning the\n\t\t\t\tprogress of the ", "@entity-type": "committee", "#text": "Committee on\n\t\t\t\tEnergy and Commerce of the House of Representatives", "@entity-id": "HIF00"}, {"#tail": " in achieving the goals identified\n\t\t\t\tin the letters described in ", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, {"#tail": " toward expediting the animal drug development process and\n\t\t\t\tthe review of the new and supplemental animal drug applications and\n\t\t\t\tinvestigational animal drug submissions during such fiscal year, the future\n\t\t\t\tplans of the ", "@entity-type": "act", "#text": "section 101(b) of the Animal Drug User Fee\n\t\t\t\tAmendments of 2013", "@value": "Animal Drug User Fee Amendments of 2013/s:101/ss:b", "@proposed": "true"}, {"#tail": " for meeting the goals, the review\n\t\t\t\ttimes for abbreviated new animal drug applications, and the administrative\n\t\t\t\tprocedures adopted by the ", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, {"#tail": " to ensure that review\n\t\t\t\ttimes for abbreviated new animal drug applications are not increased from their\n\t\t\t\tcurrent level due to activities under the user fee program.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "Beginning with fiscal year 2014, not later\n\t\t\t\tthan 120 days after the end of each fiscal year during which fees are collected\n\t\t\t\tunder this part, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(a)"}, "header": {"#tail": "\n              ", "#text": "Performance report", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "ide710374a1b3649a282c6a20d66db3469", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall prepare and submit to the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and the ", "@entity-type": "committee", "#text": "Committee on\n\t\t\t\tHealth, Education, Labor, and Pensions of the Senate", "@entity-id": "SSHR00"}, {"#tail": " a report on the\n\t\t\t\timplementation of the authority for such fees during such fiscal year and the\n\t\t\t\tuse, by the ", "@entity-type": "committee", "#text": "Committee on\n\t\t\t\tEnergy and Commerce of the House of Representatives", "@entity-id": "HIF00"}, {"#tail": ", of the fees collected during such\n\t\t\t\tfiscal year for which the report is made.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "Beginning with fiscal year 2014, not later\n\t\t\t\tthan 120 days after the end of each fiscal year during which fees are collected\n\t\t\t\tunder this part, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(b)"}, "header": {"#tail": "\n              ", "#text": "Fiscal report", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id036e8e685fd2433a9a150752fc6853c9", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall make the reports\n\t\t\t\trequired under subsections (a) and (b) available to the public on the Internet\n\t\t\t\tWeb site of the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(c)"}, "header": {"#tail": "\n              ", "#text": "Public availability", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id70c74929fa794ceda549be2e4bcdb860", "@commented": "no"}, {"#tail": "\n          ", "enum": {"#tail": "\n              ", "#text": "(d)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Reauthorization", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " with respect to the goals, and plans for meeting the goals, for\n\t\t\t\tthe process for the review of animal drug applications for the first 5 fiscal\n\t\t\t\tyears after fiscal year 2018, and for the reauthorization of this part for such\n\t\t\t\tfiscal years, the ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, {"#tail": " shall consult with\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "In developing recommendations to present to\n\t\t\t\tthe ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Consultation", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id57095eef82914448879892c2b5cfe99c", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "committee", "#text": "Committee on Health, Education, Labor,\n\t\t\t\tand Pensions of the Senate", "@entity-id": "SSHR00"}, "#text": "the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "ide111af8ca37e4693b84ca1626c83cd47", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "committee", "#text": "Committee on Energy and Commerce of the\n\t\t\t\tHouse of Representatives", "@entity-id": "HIF00"}, "#text": "the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id448d41d83bf441b3a1391bff9bad9137", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "scientific and academic experts;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id07b24380644a4aabae82feedc049e120", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "veterinary professionals;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id9008aebf19cc479e8b2fd3c7e20d0f68", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "representatives of patient and consumer\n\t\t\t\tadvocacy groups; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(E)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idd5d4740bfc954e24b85d86514a3b9cf6", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "the regulated industry.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(F)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idef604a0ab22e4a57b6ea8698e136787b", "@commented": "no"}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t\tshall\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Prior to beginning negotiations with the\n\t\t\t\tregulated industry on the reauthorization of this part, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Prior public input", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id89f90dbdd5e04ec2aa435447045e507b", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "publish a notice in the Federal Register\n\t\t\t\trequesting public input on the reauthorization;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idd1d66eb433a645658f2b64fc5667fa96", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "hold a public meeting at which the public\n\t\t\t\tmay present its views on the reauthorization, including specific suggestions\n\t\t\t\tfor changes to the goals referred to in subsection (a);", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id269baaa080b84fef91902ca8d2aa46a3", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "provide a period of 30 days after the\n\t\t\t\tpublic meeting to obtain written comments from the public suggesting changes to\n\t\t\t\tthis part; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id7496a4dca3e8451f85d7842dd3216a64", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " Internet Web site.", "@entity-type": "federal-body", "#text": "Food and Drug\n\t\t\t\tAdministration\u2019s", "@entity-id": "7524"}, "#text": "publish the comments on the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id67d013b5e00b4c48a9e36b7df2599129", "@commented": "no"}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\n\t\t\t\thold discussions with representatives of veterinary, patient, and consumer\n\t\t\t\tadvocacy groups to continue discussions of their views on the reauthorization\n\t\t\t\tand their suggestions for changes to this part as expressed under paragraph\n\t\t\t\t(2).", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Not less frequently than once every 4\n\t\t\t\tmonths during negotiations with the regulated industry, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Periodic consultation", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id9230d0a90c734dc5a1058fe99e46cfa9", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "After\n\t\t\t\tnegotiations with the regulated industry, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n                ", "#text": "Public review of\n\t\t\t\trecommendations", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id57f685acb120400697565bc2d0b43fbc", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "present the recommendations developed under\n\t\t\t\tparagraph (1) to the Congressional committees specified in such\n\t\t\t\tparagraph;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idf9b35f1dc4d6427895456dc260e75775", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "publish such recommendations in the Federal\n\t\t\t\tRegister;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idcc769eebd7dc40a8bbe143ac09353cba", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "provide for a period of 30 days for the\n\t\t\t\tpublic to provide written comments on such recommendations;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idac581df369e847d89cedc615ed466f56", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "hold a meeting at which the public may\n\t\t\t\tpresent its views on such recommendations; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id2cfd442b7abd45d9b39640e83aaaf812", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "after consideration of such public views\n\t\t\t\tand comments, revise such recommendations as necessary.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(E)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id6f12127e7ba64095b14fef4d8d658e5a", "@commented": "no"}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall transmit to ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " the revised\n\t\t\t\trecommendations under paragraph (4) a summary of the views and comments\n\t\t\t\treceived under such paragraph, and any changes made to the recommendations in\n\t\t\t\tresponse to such views and comments.", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}], "#text": "Not later\n\t\t\t\tthan January 15, 2018, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(5)"}, "header": {"#tail": "\n                ", "#text": "Transmittal of\n\t\t\t\trecommendations", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idd01a91d0528f42da94f26ccb08545148", "@commented": "no"}, {"#tail": "\n            ", "@id": "ida076c7807f1d43238f245a5a5e6d8458", "enum": {"#tail": "\n                ", "#text": "(6)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Minutes of negotiation meetings", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, {"#tail": " shall\n\t\t\t\tmake publicly available, on the Internet Web site of the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", minutes of all negotiation meetings conducted under this\n\t\t\t\tsubsection between the ", "@entity-type": "federal-body", "#text": "Food and Drug\n\t\t\t\tAdministration", "@entity-id": "7524"}, {"#tail": " and the regulated\n\t\t\t\tindustry.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "Before presenting the recommendations\n\t\t\t\tdeveloped under paragraphs (1) through (5) to ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "header": {"#tail": "\n                  ", "#text": "Public availability", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id9cb0747cfca04ad1ab544a53081714dc", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "The minutes described under subparagraph\n\t\t\t\t(A) shall summarize any substantive proposal made by any party to the\n\t\t\t\tnegotiations as well as significant controversies or differences of opinion\n\t\t\t\tduring the negotiations and their\n\t\t\t\tresolution.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n                  ", "#text": "Content", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id815564b6c0a64e78b0bf983cb962efa2", "@commented": "no"}], "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idebefb335a8394bb6b022f739b5489539", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "id169ab2424afb43bba1e9aa0871d919b9", "@commented": "no"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "id42045B5453184AC8B1E58DE58F9C326B"}, "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "idF95379A251544E6E81CF9BBCFDFA1C6E", "@commented": "no"}, {"@section-type": "subsequent-section", "#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " for filing with respect to assessing and collecting any fee\n\t\t\t required by such part for a fiscal year prior to fiscal year 2014.", "@entity-type": "federal-body", "#text": "Food and Drug\n\t\t\t Administration", "@entity-id": "7524"}, "#text": "Notwithstanding the\n\t\t\t amendments made by this title, ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ", as in effect\n\t\t\t on the day before the date of the enactment of this title, shall continue to be\n\t\t\t in effect with respect to animal drug applications and supplemental animal drug\n\t\t\t applications (as defined in such part as of such day) that on or after October\n\t\t\t 1, 2008, but before October 1, 2013, were accepted by the ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "part 4 of subchapter C of chapter VII of the\n\t\t\t Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:4"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "\n              21 U.S.C. 379j\u201311 et seq.", "@value": "usc/21/379j\u201311/etseq"}, "@parsable-cite": "usc/21/379j-11", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n        ", "#text": "105."}, "header": {"#tail": "\n        ", "#text": "Savings\n\t\t\t clause", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "idba28b0f6449e4cf594c392846a403b7d", "@commented": "no"}, {"@section-type": "subsequent-section", "#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", as amended by this\n\t\t\t title, shall be assessed for all animal drug applications and supplemental\n\t\t\t animal drug applications received on or after October 1, 2013, regardless of\n\t\t\t the date of the enactment of this Act.", "@entity-type": "act", "#text": "part 4 of subchapter C of\n\t\t\t chapter VII of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:4"}, "#text": "The amendments made by\n\t\t\t this title shall take effect on October 1, 2013, or the date of enactment of\n\t\t\t this Act, whichever is later, except that fees under ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n        ", "#text": "106."}, "header": {"#tail": "\n        ", "#text": "Effective\n\t\t\t date", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "idc9d1267aec5c4c19b7d4aa9c166e8eee", "@commented": "no"}, {"@section-type": "subsequent-section", "#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "107."}, "header": {"#tail": "\n\t\t\t\t", "#text": "Sunset dates", "@display-inline": "yes-display-inline"}, "subsection": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " shall cease to be effective October 1,\n\t\t\t 2018.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 740 of the Federal Food, Drug, and\n\t\t\t Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:740", "@proposed": "true"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "\n                21 U.S.C. 379j\u201312", "@value": "usc/21/379j\u201312", "@proposed": "true"}, "@parsable-cite": "usc/21/379j-12", "#text": "\n              ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(a)"}, "header": {"#tail": "\n          ", "#text": "Authorization", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "ida4a641c87d6f448487f5da62d52db76d", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " shall cease to be effective January 31,\n\t\t\t 2019.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 740A of the Federal Food, Drug, and\n\t\t\t Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:740A", "@proposed": "true"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "\n                21 U.S.C. 379j\u201313", "@value": "usc/21/379j\u201313", "@proposed": "true"}, "@parsable-cite": "usc/21/379j-13", "#text": "\n              ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(b)"}, "header": {"#tail": "\n          ", "#text": "Reporting requirements", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "id4cf78229349d409dbfb2ecdbcbe4b405", "@commented": "no"}, {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "(c)"}, "header": {"#tail": "\n\t\t\t\t\t", "#text": "Previous sunset provision", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "\n              ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is repealed.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 108 of the Animal Drug User Fee\n\t\t\t Amendments of 2008", "@value": "Animal Drug User Fee Amendments of 2008/s:108"}, "@entity-type": "law-citation", "#text": "\n                ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "public-law", "#text": "Public Law 110\u2013316", "@value": "public-law/110/316"}, "@parsable-cite": "pl/110/316", "#text": "\n                ", "@legal-doc": "public-law"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "header": {"#tail": "\n            ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "idF96D025B9B954D67B403EB31E8339400", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", by\n\t\t\t striking the item relating to ", "@entity-type": "act", "#text": "section 1", "@value": "Animal Drug User Fee Amendments of 2008/s:1"}, {"#tail": ".", "@entity-type": "act", "#text": "section 108", "@value": "Animal Drug User Fee Amendments of 2008/s:108"}], "#text": "The ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended in the table of contents in ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t (", "@entity-type": "act", "#text": "Animal Drug User Fee Amendments of 2008", "@value": "Animal Drug User Fee Amendments of 2008"}, "@entity-type": "law-citation", "#text": "\n                ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "public-law", "#text": "Public Law 110\u2013316", "@value": "public-law/110/316"}, "@parsable-cite": "pl/110/316", "#text": "\n                ", "@legal-doc": "public-law"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "header": {"#tail": "\n            ", "#text": "Conforming amendment", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "id704437d4593445a1b663af92ade5d290", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "id4a9f8594497e4531a4856d553c4bbacf", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "Effective November 18, 2003, ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is repealed.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 5 of\n\t\t\t the Animal Drug User Fee Act of 2003", "@value": "Animal Drug User Fee Act of 2003/s:5"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "public-law", "#text": "Public Law 108\u2013130", "@value": "public-law/108/130"}, "@parsable-cite": "pl/108/130", "#text": "\n              ", "@legal-doc": "public-law"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(d)"}, "header": {"#tail": "\n          ", "#text": "Technical clarification", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "id9d1d603607f54f548b231acd56ef8fc7", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "id0b82b2aad4a449f1a2d259581c5c328c", "@commented": "no"}], "enum": {"#tail": "\n      ", "#text": "I"}, "#tail": "\n    ", "header": {"#tail": "\n\t\t\t", "#text": "Fees relating to animal drugs", "@display-inline": "yes-display-inline"}, "#text": "\n      ", "@id": "idCAB9CAD96B1741ABBCE4EB6FD7B2A456", "@commented": "no"}, {"@level-type": "subsequent", "section": [{"@section-type": "subsequent-section", "#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "201."}, "header": {"#tail": "\n\t\t\t\t", "#text": "Short title; finding", "@display-inline": "yes-display-inline"}, "subsection": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "quote": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "act", "#text": "Animal Generic Drug User Fee Amendments of 2013", "@value": "Animal Generic Drug User Fee Amendments of 2013", "@proposed": "true"}, "#text": "\n              "}, "#text": "This title may be cited as the\n\t\t\t ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(a)"}, "header": {"#tail": "\n          ", "#text": "Short title", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "id5B7258CB595642B195BCA087E66A0A86", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": "\n\t\t\t to the ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, {"#tail": " and the ", "@entity-type": "committee", "#text": "Chairman of the Committee on Energy and Commerce of the House of\n\t\t\t Representatives", "@entity-id": "HIF00"}, {"#tail": " as set forth in the Congressional Record.", "@entity-type": "committee", "#text": "Chairman of the Committee on Health, Education, Labor,\n\t\t\t and Pensions of the Senate", "@entity-id": "SSHR00"}], "#text": "The fees authorized by this title will be\n\t\t\t dedicated toward expediting the generic new animal drug development process and\n\t\t\t the review of abbreviated applications for generic new animal drugs,\n\t\t\t supplemental abbreviated applications for generic new animal drugs, and\n\t\t\t investigational submissions for generic new animal drugs as set forth in the\n\t\t\t goals identified in the letters from the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(b)"}, "header": {"#tail": "\n          ", "#text": "Finding", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "id3676933E1331421F958CC0D6921A8692", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "id7BD7ADAD8E32489AACA44A75A67EB6D3", "@commented": "no"}, {"@section-type": "subsequent-section", "#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended to\n\t\t\t read as follows:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 741\n\t\t\t of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:741"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "\n              21 U.S.C. 379j\u201321"}, "@parsable-cite": "usc/21/379j-21", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n        ", "#text": "202."}, "header": {"#tail": "\n        ", "#text": "Authority to assess and use generic new\n\t\t\t animal drug fees", "@display-inline": "yes-display-inline"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "section": {"@section-type": "subsequent-section", "#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "741."}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Authority to assess and use generic new\n\t\t\t\tanimal drug fees", "@display-inline": "yes-display-inline"}, "subsection": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall assess and collect fees in accordance with this section as\n\t\t\t\tfollows:", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Beginning with respect to fiscal year 2009,\n\t\t\t\tthe ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(a)"}, "header": {"#tail": "\n              ", "#text": "Types of fees", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "@id": "idd033dcc8694346e9bfea5f744da4e5e8", "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Abbreviated application fee", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Each person that submits, on or after July\n\t\t\t\t1, 2008, an abbreviated application for a generic new animal drug shall be\n\t\t\t\tsubject to a fee as established in subsection (c) for such an\n\t\t\t\tapplication.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "header": {"#tail": "\n                  ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id64e19cdb78e846eb9618119a878bcb6e", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "The fee required by subparagraph (A) shall\n\t\t\t\tbe due upon submission of the abbreviated application.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n                  ", "#text": "Payment", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "iddf1c179e7f89415cb864455241acc50c", "@commented": "no"}, {"#tail": "\n                ", "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "If an abbreviated application was submitted\n\t\t\t\tby a person that paid the fee for such application, was accepted for filing,\n\t\t\t\tand was not approved or was withdrawn (without a waiver or refund), the\n\t\t\t\tsubmission of an abbreviated application for the same product by the same\n\t\t\t\tperson (or the person\u2019s licensee, assignee, or successor) shall not be subject\n\t\t\t\tto a fee under subparagraph (A).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "header": {"#tail": "\n                    ", "#text": "Previously filed application", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "idf1a2fedb5ba147c694c99c050050e03d", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t\tand submitted on or after October 1, 2013 shall be subject to a fee equal to 50\n\t\t\t\tpercent of the amount of the abbreviated application fee established in\n\t\t\t\tsubsection (c).", "@entity-type": "act", "#text": "section 512(d)(4)", "@value": "Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:4"}, "#text": "An\n\t\t\t\tabbreviated application which is subject to the criteria in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "header": {"#tail": "\n                    ", "#text": "Certain abbreviated applications involving\n\t\t\t\tcombination animal drugs", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "idf6c5602f895c487eab23ff78be8b7782", "@commented": "no"}], "enum": {"#tail": "\n                  ", "#text": "(C)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "Exceptions", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idcacc9bc274074a8db26b6e5af3176db4", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\n\t\t\t\trefund 75 percent of the fee paid under subparagraph (B) for any abbreviated\n\t\t\t\tapplication which is refused for filing.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "header": {"#tail": "\n                  ", "#text": "Refund of fee if application refused for\n\t\t\t\tfiling", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id700c5176ac0f4e729575ac629c0538dd", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may\n\t\t\t\trefund the fee or portion of the fee paid under subparagraph (B) if no\n\t\t\t\tsubstantial work was performed on the application after the application was\n\t\t\t\tfiled. The ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall have the sole discretion to refund the fee under\n\t\t\t\tthis subparagraph. A determination by the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " concerning a refund under\n\t\t\t\tthis subparagraph shall not be reviewable.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "If an abbreviated\n\t\t\t\tapplication is withdrawn after the application was filed, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(E)"}, "header": {"#tail": "\n                  ", "#text": "Refund of fee if application\n\t\t\t\twithdrawn", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id52f66165be4740efa589fcf66f4f4231", "@commented": "no"}], "@commented": "no"}, {"#tail": "\n              ", "@id": "idfd11ae881c8a4a8395dfe4a2a77d51bd", "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Generic new animal drug product\n\t\t\t\tfee", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "subparagraph": [{"continuation-text": {"#tail": "\n                ", "@continuation-text-level": "subparagraph", "#text": "shall pay for each such generic\n\t\t\t\tnew animal drug product the annual fee established in subsection (c).", "@commented": "no"}, "#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "Each person\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";\n\t\t\t\tand", "@entity-type": "act", "#text": "section 510", "@value": "Federal Food, Drug, and Cosmetic Act/s:510"}, "#text": "who is named as the applicant in an\n\t\t\t\tabbreviated application or supplemental abbreviated application for a generic\n\t\t\t\tnew animal drug product which has been submitted for listing under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "idAAC47F3697D44D29AC81C4CF403D37F4", "@commented": "no"}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " an abbreviated application or supplemental abbreviated\n\t\t\t\tapplication,", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "who, after September 1, 2008, had pending\n\t\t\t\tbefore the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id22C71518F6FC452C98C0C0B94BC7D85A", "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "iddab15399c61c4d0a8035ebba52405e39", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", or is submitted for relisting under ", "@entity-type": "act", "#text": "section 510", "@value": "Federal Food, Drug, and Cosmetic Act/s:510"}, {"#tail": " if\n\t\t\t\tthe generic new animal drug product has been withdrawn from listing and\n\t\t\t\trelisted. After such fee is paid for that fiscal year, such fee shall be due\n\t\t\t\teach subsequent fiscal year that the product remains listed, upon the later\n\t\t\t\tof\u2014", "@entity-type": "act", "#text": "section 510", "@value": "Federal Food, Drug, and Cosmetic Act/s:510"}], "#text": "Such fee shall be payable for the fiscal\n\t\t\t\tyear in which the generic new animal drug product is first submitted for\n\t\t\t\tlisting under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the first business day after the date of\n\t\t\t\tenactment of an appropriations Act providing for the collection and obligation\n\t\t\t\tof fees for such fiscal year under this section; or", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id7bddf23393ad4b39b10d88411c43cad6", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "January 31 of each year.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id8830eb3b7c8748c193ac55db8ec8f2cd", "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "Payment; fee due date", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id211fc9136c594c11ba4e35b782475d93", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Such fee shall be paid only once for each\n\t\t\t\tgeneric new animal drug product for a fiscal year in which the fee is\n\t\t\t\tpayable.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "header": {"#tail": "\n                  ", "#text": "Limitation", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id891f78304ddc40e0a2671e398b8eb9d8", "@commented": "no"}], "@commented": "no"}, {"#tail": "\n            ", "@id": "id6557cb8279b544cbb0c55ab780769fc7", "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Generic new animal drug sponsor\n\t\t\t\tfee", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "subparagraph": [{"continuation-text": {"#tail": "\n                ", "@continuation-text-level": "subparagraph", "#text": "shall be assessed an annual\n\t\t\t\tgeneric new animal drug sponsor fee as established under subsection (c).", "@commented": "no"}, "#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "Each person\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "who meets the definition of a generic new\n\t\t\t\tanimal drug sponsor within a fiscal year; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id3d9927c3f8ca4d9a86d2ca1c3fea48ce", "@commented": "no"}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " an abbreviated application, a supplemental abbreviated\n\t\t\t\tapplication, or an investigational submission,", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "who, after September 1, 2008, had pending\n\t\t\t\tbefore the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id6ed44938f43440c286c689f69dcdbf4d", "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "iddd8b31386bc8451f9cafcf8812045a00", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "Such fee shall be due each fiscal year upon\n\t\t\t\tthe later of\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the first business day after the date of\n\t\t\t\tenactment of an appropriations Act providing for the collection and obligation\n\t\t\t\tof fees for such fiscal year under this section; or", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "idf3f3c6043fcd42a8adc1d78c4f59d909", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "January 31 of each year.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id7e94ffff524241c29c0f544d1b328f44", "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "Payment; fee due date", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id973e315abc5b4c83ba5c0ca8a28c2dd4", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "Each generic new animal drug sponsor shall\n\t\t\t\tpay only 1 such fee each fiscal year, as follows:", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "100 percent of the amount of the generic\n\t\t\t\tnew animal drug sponsor fee published for that fiscal year under subsection (c)\n\t\t\t\tfor an applicant with more than 6 approved abbreviated applications.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id1e219392f0c9409ba632949563e83795", "@commented": "no"}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "75 percent of the amount of the generic new\n\t\t\t\tanimal drug sponsor fee published for that fiscal year under subsection (c) for\n\t\t\t\tan applicant with more than 1 and fewer than 7 approved abbreviated\n\t\t\t\tapplications.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "ida54fb62d685f40789260736565e74c79", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "50 percent of the amount of the generic new\n\t\t\t\tanimal drug sponsor fee published for that fiscal year under subsection (c) for\n\t\t\t\tan applicant with 1 or fewer approved abbreviated applications.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(iii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "idb071d68510344c6387857401259a5fca", "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "Amount of fee", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id5beff016510541e2b04af8839e31f8b0", "@commented": "no"}], "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idA929B54902514A168CBA747A059C7C37", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Subject to subsections (c), (d), (f), and\n\t\t\t\t(g), the fees required under subsection (a) shall be established to generate\n\t\t\t\tfee revenue amounts as follows:", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(b)"}, "header": {"#tail": "\n              ", "#text": "Fee amounts", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "The total fee revenues\n\t\t\t\tto be collected in abbreviated application fees under subsection (a)(1) shall\n\t\t\t\tbe $1,832,000 for fiscal year 2014, $1,736,000 for fiscal year 2015, $1,857,000\n\t\t\t\tfor fiscal year 2016, $1,984,000 for fiscal year 2017, and $2,117,000 for\n\t\t\t\tfiscal year 2018.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Total fee revenues for application\n\t\t\t\tfees", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idb58dd700a9284e1a9d8f8fc7404cc390", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "The total fee revenues\n\t\t\t\tto be collected in generic new animal drug product fees under subsection (a)(2)\n\t\t\t\tshall be $2,748,000 for fiscal year 2014, $2,604,000 for fiscal year 2015,\n\t\t\t\t$2,786,000 for fiscal year 2016, $2,976,000 for fiscal year 2017, and\n\t\t\t\t$3,175,000 for fiscal year 2018.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Total fee revenues for product\n\t\t\t\tfees", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id5669b7ac40eb48b79412de7b1b69dc28", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "The total fee revenues\n\t\t\t\tto be collected in generic new animal drug sponsor fees under subsection (a)(3)\n\t\t\t\tshall be $2,748,000 for fiscal year 2014, $2,604,000 for fiscal year 2015,\n\t\t\t\t$2,786,000 for fiscal year 2016, $2,976,000 for fiscal year 2017, and\n\t\t\t\t$3,175,000 for fiscal year 2018.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Total fee revenues for sponsor\n\t\t\t\tfees", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id051a16f1c29d483f8b09af6298f78f2a", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id1c956cf667cb4f9ca80915cb7e2b8665", "@commented": "no"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(c)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Annual fee setting; adjustments", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall establish, 60 days\n\t\t\t\tbefore the start of each fiscal year beginning after September 30, 2008, for\n\t\t\t\tthat fiscal year, abbreviated application fees, generic new animal drug sponsor\n\t\t\t\tfees, and generic new animal drug product fees, based on the revenue amounts\n\t\t\t\testablished under subsection (b) and the adjustments provided under this\n\t\t\t\tsubsection.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Annual fee setting", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idb497e2af466147f28ffd9808017b1da2", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "The fee revenues shall be adjusted each\n\t\t\t\tfiscal year after fiscal year 2014 to reflect changes in review workload. With\n\t\t\t\trespect to such adjustment:", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Workload adjustment", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id2b530be4ba344a7c8472d1472619bf1e", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " based on a weighted average of the change in the total number of\n\t\t\t\tabbreviated applications for generic new animal drugs, manufacturing\n\t\t\t\tsupplemental abbreviated applications for generic new animal drugs,\n\t\t\t\tinvestigational generic new animal drug study submissions, and investigational\n\t\t\t\tgeneric new animal drug protocol submissions submitted to the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ". The\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall publish in the Federal Register the fees resulting from this\n\t\t\t\tadjustment and the supporting methodologies.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "This adjustment shall be determined by the\n\t\t\t\t", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idce55f0013c2843629bc3559c17c3ff6d", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Under no circumstances shall this workload\n\t\t\t\tadjustment result in fee revenues for a fiscal year that are less than the fee\n\t\t\t\trevenues for that fiscal year established in subsection (b).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idc839937aeed44f2398c5cd749fee45df", "@commented": "no"}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may, in\n\t\t\t\taddition to other adjustments under this subsection, further increase the fees\n\t\t\t\tunder this section, if such an adjustment is necessary, to provide for up to 3\n\t\t\t\tmonths of operating reserves of carryover user fees for the process for the\n\t\t\t\treview of abbreviated applications for generic new animal drugs for the first 3\n\t\t\t\tmonths of fiscal year 2019. If the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " has carryover\n\t\t\t\tbalances for the process for the review of abbreviated applications for generic\n\t\t\t\tnew animal drugs in excess of 3 months of such operating reserves, then this\n\t\t\t\tadjustment shall not be made. If this adjustment is necessary, then the\n\t\t\t\trationale for the amount of the increase shall be contained in the annual\n\t\t\t\tnotice setting fees for fiscal year 2018.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "For fiscal year 2018, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Final year adjustment", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id79f461a2102d4ba5ae16865000a62050", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "The total amount of fees charged, as\n\t\t\t\tadjusted under this subsection, for a fiscal year may not exceed the total\n\t\t\t\tcosts for such fiscal year for the resources allocated for the process for the\n\t\t\t\treview of abbreviated applications for generic new animal drugs.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n                ", "#text": "Limit", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idab55f7fd91134a609c1f3553647115d0", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idf6f2311b96bd43de92f540e7ea172f1b", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall grant a waiver from or\n\t\t\t\ta reduction of 1 or more fees assessed under subsection (a) where the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": "\n\t\t\t\tfinds that the generic new animal drug is intended solely to provide for a\n\t\t\t\tminor use or minor species indication.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(d)"}, "header": {"#tail": "\n              ", "#text": "Fee waiver or reduction", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id474bf912dc054a5394e194a0c8ccd9d1", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " until all fees owed by such person have been paid. An investigational\n\t\t\t\tsubmission for a generic new animal drug that is submitted by a person subject\n\t\t\t\tto fees under subsection (a) shall be considered incomplete and shall not be\n\t\t\t\taccepted for review by the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " until all fees owed by such person have\n\t\t\t\tbeen paid. The ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may discontinue review of any abbreviated application\n\t\t\t\tfor a generic new animal drug, supplemental abbreviated application for a\n\t\t\t\tgeneric new animal drug, or investigational submission for a generic new animal\n\t\t\t\tdrug from a person if such person has not submitted for payment all fees owed\n\t\t\t\tunder this section by 30 days after the date upon which they are due.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "An abbreviated application for a generic\n\t\t\t\tnew animal drug submitted by a person subject to fees under subsection (a)\n\t\t\t\tshall be considered incomplete and shall not be accepted for filing by the\n\t\t\t\t", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(e)"}, "header": {"#tail": "\n              ", "#text": "Effect of failure To pay fees", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idd9cb7aedcb3d4858b093b99de0a4b2f7", "@commented": "no"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(f)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Assessment of fees", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " for such fiscal\n\t\t\t\tyear (excluding the amount of fees appropriated for such fiscal year) are equal\n\t\t\t\tto or greater than the amount of appropriations for the salaries and expenses\n\t\t\t\tof the ", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, {"#tail": " for the fiscal year 2003 (excluding the\n\t\t\t\tamount of fees appropriated for such fiscal year) multiplied by the adjustment\n\t\t\t\tfactor applicable to the fiscal year involved.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "Fees may not be assessed under subsection\n\t\t\t\t(a) for a fiscal year beginning after fiscal year 2008 unless appropriations\n\t\t\t\tfor salaries and expenses of the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Limitation", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id9edc3a6a8b1344e084165fab3c9608df", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " does not assess fees under\n\t\t\t\tsubsection (a) during any portion of a fiscal year because of paragraph (1) and\n\t\t\t\tif at a later date in such fiscal year the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may assess such fees, the\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may assess and collect such fees, without any modification in the\n\t\t\t\trate, for abbreviated applications, generic new animal drug sponsors, and\n\t\t\t\tgeneric new animal drug products at any time in such fiscal year\n\t\t\t\tnotwithstanding the provisions of subsection (a) relating to the date fees are\n\t\t\t\tto be paid.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "If the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Authority", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id9a9badbc35d5453db9629e9ff10fb752", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idb22582a4cdf04bd8babc79b17fd0c976", "@commented": "no"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(g)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Crediting and availability of fees", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " salaries and expenses appropriation account without fiscal\n\t\t\t\tyear limitation to such appropriation account for salary and expenses with such\n\t\t\t\tfiscal year limitation. The sums transferred shall be available solely for the\n\t\t\t\tprocess for the review of abbreviated applications for generic new animal\n\t\t\t\tdrugs.", "@entity-type": "federal-body", "#text": "Food and\n\t\t\t\tDrug Administration", "@entity-id": "7524"}, "#text": "Subject to paragraph (2)(C), fees\n\t\t\t\tauthorized under subsection (a) shall be collected and available for obligation\n\t\t\t\tonly to the extent and in the amount provided in advance in appropriations\n\t\t\t\tActs. Such fees are authorized to be appropriated to remain available until\n\t\t\t\texpended. Such sums as may be necessary may be transferred from the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id5b018b8f434347bcbbc30f69a9b09049", "@commented": "no"}, {"#tail": "\n              ", "@id": "idc9b1a94605274f0e907affff1e4955c1", "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Collections and appropriation acts", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "The fees authorized by this section\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "subject to subparagraph (C), shall be\n\t\t\t\tcollected and available in each fiscal year in an amount not to exceed the\n\t\t\t\tamount specified in appropriation Acts, or otherwise made available for\n\t\t\t\tobligation for such fiscal year; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id347363eabb5742ed8aa7e3ebe4710571", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to be engaged in such process) over\n\t\t\t\tsuch costs, excluding costs paid from fees collected under this section, for\n\t\t\t\tfiscal year 2008 multiplied by the adjustment factor.", "@entity-type": "federal-body", "#text": "Department of Health and Human Services", "@entity-id": "7500"}, "#text": "shall be available to defray increases in\n\t\t\t\tthe costs of the resources allocated for the process for the review of\n\t\t\t\tabbreviated applications for generic new animal drugs (including increases in\n\t\t\t\tsuch costs for an additional number of full-time equivalent positions in the\n\t\t\t\t", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "ide9db51ba72164628b296549fe1ed056a", "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id9062c4e0e546425985494248120ca399", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall be considered to have\n\t\t\t\tmet the requirements of subparagraph (A)(ii) in any fiscal year if the costs\n\t\t\t\tfunded by appropriations and allocated for the process for the review of\n\t\t\t\tabbreviated applications for generic new animal drugs\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "are not more than 3 percent below the level\n\t\t\t\tspecified in subparagraph (A)(ii); or", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "@id": "id4fb5d0dd6a4f489e9fecaeae3097a116", "@commented": "no"}, {"#tail": "\n                ", "@id": "id64f07a2293324659bd822cce3a163897", "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                    ", "subclause": [{"#tail": "\n                    ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t\t", "#text": "are more than 3 percent below the level\n\t\t\t\tspecified in subparagraph (A)(ii), and fees assessed for the fiscal year\n\t\t\t\tfollowing the subsequent fiscal year are decreased by the amount in excess of 3\n\t\t\t\tpercent by which such costs fell below the level specified in subparagraph\n\t\t\t\t(A)(ii); and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                      ", "#text": "(I)"}, "@display-inline": "yes-display-inline", "#text": "\n                      ", "@id": "id1577C26DF6A14192927D1A054851AF0E", "@commented": "no"}, {"@indent": "up1", "#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t\t", "#text": "such costs are not more than 5 percent\n\t\t\t\tbelow the level specified in subparagraph (A)(ii).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                      ", "#text": "(II)"}, "@display-inline": "no-display-inline", "#text": "\n                      ", "@id": "id655045F5D8054D87866A62190C14BEE1", "@commented": "no"}], "@commented": "no"}], "header": {"#tail": "\n                  ", "#text": "Compliance", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idd23dbbcd51834e5889d81909ce62b7ae", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " in accordance with authority provided in advance in a prior\n\t\t\t\tyear appropriations Act.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Payment of fees authorized under this\n\t\t\t\tsection for a fiscal year, prior to the due date for such fees, may be accepted\n\t\t\t\tby the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "header": {"#tail": "\n                  ", "#text": "Provision for early payments", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id19580c37f8ff4d26ad08a56edbba00a9", "@commented": "no"}], "@commented": "no"}, {"#text": "\n                ", "continuation-text": {"#tail": "\n              ", "@continuation-text-level": "paragraph", "#text": "as adjusted to reflect adjustments in\n\t\t\t\tthe total fee revenues made under this section and changes in the total amounts\n\t\t\t\tcollected by abbreviated application fees, generic new animal drug sponsor\n\t\t\t\tfees, and generic new animal drug product fees.", "@commented": "no"}, "#tail": "\n              ", "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Authorization of\n\t\t\t\tappropriations", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "{http://namespaces.cato.org/catoxml}block-entity": {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "There are\n\t\t\t\tauthorized to be appropriated ", "{http://namespaces.cato.org/catoxml}property": {"#tail": "\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "act", "#text": "this section", "@value": "Federal Food, Drug, and Cosmetic Act/s:741", "@proposed": "true"}, "#text": "for fees under ", "@name": "purpose"}, "@display-inline": "yes-display-inline"}, "@entity-type": "auth-auth-approp", "#text": "\n                  ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ";", "#text": "$7,328,000 for fiscal year 2014", "@amount": "7328000", "@year": "2014"}, "#text": "\n                      ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idac5784dfb4ef44e893b26b7cde670052", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ";", "#text": "$6,944,000 for fiscal year 2015", "@amount": "6944000", "@year": "2015"}, "#text": "\n                      ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idd10cd8580e5347f9ad83be3857ca567e", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ";", "#text": "$7,429,000 for fiscal year 2016", "@amount": "7429000", "@year": "2016"}, "#text": "\n                      ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idef95bb14183f45168b8ef8e5500fc69d", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": "; and", "#text": "$7,936,000 for fiscal year 2017", "@amount": "7936000", "@year": "2017"}, "#text": "\n                      ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id70956af7bdf146d9bb768f9aee6dc5a5", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ";", "#text": "$8,467,000 for fiscal year 2018", "@amount": "8467000", "@year": "2018"}, "#text": "\n                      ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(E)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id4d2c2be7c3eb425d86e3526101b3071c", "@commented": "no"}]}, "@id": "idabfe73e158f249abb0232b9ef342c788", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " as provided in\n\t\t\t\tparagraph (1), and shall be subtracted from the amount of fees that would\n\t\t\t\totherwise be authorized to be collected under this section pursuant to\n\t\t\t\tappropriation Acts for fiscal year 2018.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "#text": "If the sum of the cumulative amount of fees\n\t\t\t\tcollected under this section for the fiscal years 2014 through 2016 and the\n\t\t\t\tamount of fees estimated to be collected under this section for fiscal year\n\t\t\t\t2017 exceeds the cumulative amount appropriated under paragraph (3) for the\n\t\t\t\tfiscal years 2014 through 2017, the excess amount shall be credited to the\n\t\t\t\tappropriation account of the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n                ", "#text": "Offset", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id2aa2ca2dae8c4cb69c85a6a8d27d64fe", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idfb4a0834e4e44bca971de9ef32b1cb8a", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " does not\n\t\t\t\treceive payment of a fee assessed under subsection (a) within 30 days after it\n\t\t\t\tis due, such fee shall be treated as a claim of the United States Government\n\t\t\t\tsubject to ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "uscode", "#text": "subchapter II of ", "external-xref": {"#tail": " of title 31, United States Code", "@parsable-cite": "usc-chapter/31/37", "#text": "chapter 37", "@legal-doc": "usc-chapter"}, "@value": "usc-chapter/31/37/II"}], "#text": "In any case where the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(h)"}, "header": {"#tail": "\n              ", "#text": "Collection of unpaid fees", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id985851c562cc46b7bee05be65b7538b3", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " a written request for such waiver, reduction, or refund not\n\t\t\t\tlater than 180 days after such fee is due.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "To qualify for\n\t\t\t\tconsideration for a waiver or reduction under subsection (d), or for a refund\n\t\t\t\tof any fee collected in accordance with subsection (a), a person shall submit\n\t\t\t\tto the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(i)"}, "header": {"#tail": "\n              ", "#text": "Written requests for waivers, reductions,\n\t\t\t\tand refunds", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id5e73490d23ae4a99bb861fae59b1c633", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", for officers, employees, and advisory committees not\n\t\t\t\tengaged in the process of the review of abbreviated applications for generic\n\t\t\t\tnew animal drugs, be reduced to offset the number of officers, employees, and\n\t\t\t\tadvisory committees so engaged.", "@entity-type": "federal-body", "#text": "Department of\n\t\t\t\tHealth and Human Services", "@entity-id": "7500"}, "#text": "This section may not be construed to\n\t\t\t\trequire that the number of full-time equivalent positions in the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(j)"}, "header": {"#tail": "\n              ", "#text": "Construction", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id29448b8b6ce54925be18ca43cca6dc34", "@commented": "no"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ":", "@entity-type": "act", "#text": "section 742", "@value": "Federal Food, Drug, and Cosmetic Act/s:742"}, "#text": "In this section and ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(k)"}, "header": {"#tail": "\n              ", "#text": "Definitions", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "text": {"{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ". Such\n\t\t\t\tterm does not include a supplemental abbreviated application for a generic new\n\t\t\t\tanimal drug.", "@entity-type": "act", "#text": "section 512(b)(2)", "@value": "Federal Food, Drug, and Cosmetic Act/s:512/ss:b/p:2"}, "quote": [{"#tail": " and\n\t\t\t\t", "#text": "abbreviated application for a generic new animal drug"}, {"#tail": " mean an abbreviated application for the\n\t\t\t\tapproval of any generic new animal drug submitted under ", "#text": "abbreviated application"}], "#tail": "\n\t\t\t\t\t\t\t", "#text": "The terms\n\t\t\t\t", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Abbreviated application for a generic new\n\t\t\t\tanimal drug", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id9e789c630f534fc1a17705f4711f20db", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "term": {"#tail": "\n\t\t\t\tapplicable to a fiscal year is the Consumer Price Index for all urban consumers\n\t\t\t\t(all items; United States city average) for October of the preceding fiscal\n\t\t\t\tyear divided by\u2014", "#text": "adjustment factor"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Adjustment factor", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "ida30b674c75294162b443730015f16a0c", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "for purposes of subsection (f)(1), such\n\t\t\t\tIndex for October 2002; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "iddc627bb6c4f14deead951018b3911e85", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "for purposes of subsection (g)(2)(A)(ii),\n\t\t\t\tsuch Index for October 2007.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idf3c77447412d4cf6b311d82382553bcc", "@commented": "no"}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "term": {"#tail": " means the expenses in connection with the\n\t\t\t\tprocess for the review of abbreviated applications for generic new animal drugs\n\t\t\t\tfor\u2014", "#text": "costs of\n\t\t\t\tresources allocated for the process for the review of abbreviated applications\n\t\t\t\tfor generic new animal drugs"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Costs of resources allocated for the\n\t\t\t\tprocess for the review of abbreviated applications for generic new animal\n\t\t\t\tdrugs", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id5673217cf52d44d59d2788efbdfd28dc", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", contractors of the ", "@entity-type": "federal-body", "#text": "Food and Drug\n\t\t\t\tAdministration", "@entity-id": "7524"}, {"#tail": ", advisory\n\t\t\t\tcommittees consulted with respect to the review of specific abbreviated\n\t\t\t\tapplications, supplemental abbreviated applications, or investigational\n\t\t\t\tsubmissions, and costs related to such officers, employees, committees, and\n\t\t\t\tcontractors, including costs for travel, education, and recruitment and other\n\t\t\t\tpersonnel activities;", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "officers and employees of the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idb6172e6188464671aba1cd8e4c8cf6dd", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "management of information, and the\n\t\t\t\tacquisition, maintenance, and repair of computer resources;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id284f904c024147579ef83105e08e3c5e", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "leasing, maintenance, renovation, and\n\t\t\t\trepair of facilities and acquisition, maintenance, and repair of fixtures,\n\t\t\t\tfurniture, scientific equipment, and other necessary materials and supplies;\n\t\t\t\tand", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id86ce78a8844748a0b5cc9bb6cc761dff", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "collecting fees under this section and\n\t\t\t\taccounting for resources allocated for the review of abbreviated applications,\n\t\t\t\tsupplemental abbreviated applications, and investigational submissions.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id17faa74bca3b4c2aa225ba900b4a3bc2", "@commented": "no"}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": "\n\t\t\t\tmeans, with respect to a generic new animal drug product, a finished dosage\n\t\t\t\tform which is approved for administration to an animal without substantial\n\t\t\t\tfurther manufacturing. Such term includes generic new animal drug products\n\t\t\t\tintended for mixing in animal feeds.", "#text": "final dosage form"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n                ", "#text": "Final dosage form", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id20b1eb3b785c4ec390293f0af646feab", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": " means a new animal drug that is the subject of an abbreviated\n\t\t\t\tapplication.", "#text": "generic new animal\n\t\t\t\tdrug"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(5)"}, "header": {"#tail": "\n                ", "#text": "Generic new animal drug", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id272826959c1744dcb5bed307340b9b2c", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": " means each specific strength or\n\t\t\t\tpotency of a particular active ingredient or ingredients in final dosage form\n\t\t\t\tmarketed by a particular manufacturer or distributor, which is uniquely\n\t\t\t\tidentified by the labeler code and product code portions of the national drug\n\t\t\t\tcode, and for which an abbreviated application for a generic new animal drug or\n\t\t\t\ta supplemental abbreviated application has been approved.", "#text": "generic new animal drug product"}, "#text": "The term\n\t\t\t\t", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(6)"}, "header": {"#tail": "\n                ", "#text": "Generic new animal drug\n\t\t\t\tproduct", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id58927ba3757e4d39a57beee909079257", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", or a person who has submitted an investigational submission for a\n\t\t\t\tgeneric new animal drug that has not been terminated or otherwise rendered\n\t\t\t\tinactive by the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "term": {"#tail": " means either an applicant named in\n\t\t\t\tan abbreviated application for a generic new animal drug that has not been\n\t\t\t\twithdrawn by the applicant and for which approval has not been withdrawn by the\n\t\t\t\t", "#text": "generic new animal drug sponsor"}, "#text": "The term\n\t\t\t\t", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(7)"}, "header": {"#tail": "\n                ", "#text": "Generic new animal drug\n\t\t\t\tsponsor", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id44ea039cf7554eab87ade377979465d6", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "quote": {"#tail": " mean\u2014", "#text": "investigational submission"}, "term": {"#tail": " and\n\t\t\t\t", "#text": "investigational submission for a generic new animal drug"}, "#text": "The terms\n\t\t\t\t", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(8)"}, "header": {"#tail": "\n                ", "#text": "Investigational submission for a generic\n\t\t\t\tnew animal drug", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idfde766ad6a094af99ff2af00b289ee00", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " for a generic new animal drug\n\t\t\t\tintended to be the subject of an abbreviated application or a supplemental\n\t\t\t\tabbreviated application; or", "@entity-type": "act", "#text": "section 512(j)", "@value": "Federal Food, Drug, and Cosmetic Act/s:512/ss:j"}, "#text": "the filing of a claim for an\n\t\t\t\tinvestigational exemption under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id5b080929c7b0475391d5f38fee5aaf53", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to evaluate the safety or effectiveness of a\n\t\t\t\tgeneric new animal drug in the event of the filing of an abbreviated\n\t\t\t\tapplication or supplemental abbreviated application for such drug.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "the submission of information for the\n\t\t\t\tpurpose of enabling the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id7b92f5fd2e404d55a274cd8bd2ab2253", "@commented": "no"}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ").", "@entity-type": "act", "#text": "section 735(11)", "@value": "Federal Food, Drug, and Cosmetic Act/s:735/p:11"}, "term": {"#tail": " includes an\n\t\t\t\taffiliate thereof (as such term is defined in ", "#text": "person"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(9)"}, "header": {"#tail": "\n                ", "#text": "Person", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id762a596bef624fce92f8f6688bb0ef3b", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " with respect to the review of abbreviated\n\t\t\t\tapplications, supplemental abbreviated applications, and investigational\n\t\t\t\tsubmissions:", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "term": {"#tail": " means the\n\t\t\t\tfollowing activities of the ", "#text": "process for the review of\n\t\t\t\tabbreviated applications for generic new animal drugs"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(10)"}, "header": {"#tail": "\n                ", "#text": "Process for the review of abbreviated\n\t\t\t\tapplications for generic new animal drugs", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idcef769cd12b94d8790c5c79ae91e12ce", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "The activities necessary for the review of\n\t\t\t\tabbreviated applications, supplemental abbreviated applications, and\n\t\t\t\tinvestigational submissions.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id1d28224fcbba42f78f55cd33f84cdb7f", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "The issuance of action letters which\n\t\t\t\tapprove abbreviated applications or supplemental abbreviated applications or\n\t\t\t\twhich set forth in detail the specific deficiencies in abbreviated\n\t\t\t\tapplications, supplemental abbreviated applications, or investigational\n\t\t\t\tsubmissions and, where appropriate, the actions necessary to place such\n\t\t\t\tapplications, supplemental applications, or submissions in condition for\n\t\t\t\tapproval.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idca7ad63ac97d4c4b9af9c27fbc472598", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t\treview of pending abbreviated applications, supplemental abbreviated\n\t\t\t\tapplications, and investigational submissions.", "@entity-type": "federal-body", "#text": "Secretary\u2019s", "@entity-id": "7500"}, "#text": "The inspection of generic new animal drug\n\t\t\t\testablishments and other facilities undertaken as part of the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id6b7613a72e984e13a81702dc0a34d4d6", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Monitoring of research conducted in\n\t\t\t\tconnection with the review of abbreviated applications, supplemental\n\t\t\t\tabbreviated applications, and investigational submissions.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id27e26d94202a4fb1a715b9901fb0b98e", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "The development of regulations and policy\n\t\t\t\trelated to the review of abbreviated applications, supplemental abbreviated\n\t\t\t\tapplications, and investigational submissions.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(E)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id1f297d9205094f2e9f3f0ec77f835af8", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Development of standards for products\n\t\t\t\tsubject to review.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(F)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idbbdb71b7975c4d2cae850f74a353f26d", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Meetings between the agency and the generic\n\t\t\t\tnew animal drug sponsor.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(G)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idfe37190931f943e8986405691c20be94", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Review of advertising and labeling prior to\n\t\t\t\tapproval of an abbreviated application or supplemental abbreviated application,\n\t\t\t\tbut not after such application has been approved.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(H)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id682dd24a3be843ecb77a23b85545731f", "@commented": "no"}]}, {"#tail": "\n            ", "text": {"{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to approve a change in an approved abbreviated\n\t\t\t\tapplication.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "quote": [{"#tail": " and ", "#text": "supplemental abbreviated application for a generic new animal\n\t\t\t\tdrug"}, {"#tail": " mean a\n\t\t\t\trequest to the ", "#text": "supplemental abbreviated application"}], "#tail": "\n\t\t\t\t\t\t\t", "#text": "The\n\t\t\t\tterms ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(11)"}, "header": {"#tail": "\n                ", "#text": "Supplemental abbreviated application for\n\t\t\t\tgeneric new animal drug", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id3415d393a8314ab99d600513ca224815", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idBA43A3FF5D0B4A07A6EBEDE134DBD544", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "idCE203E7223C9448BA10C1238E884DF6F", "@commented": "no"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "id317629433EE749E59AA433810759A5AE"}, "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "id105B4517DF0E45CC895D417541929E33", "@commented": "no"}, {"@section-type": "subsequent-section", "#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended to read\n\t\t\t as follows:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 742 of\n\t\t\t the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:742"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "\n              21 U.S.C. 379j\u201322"}, "@parsable-cite": "usc/21/379j-22", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n        ", "#text": "203."}, "header": {"#tail": "\n        ", "#text": "Reauthorization; reporting\n\t\t\t requirements", "@display-inline": "yes-display-inline"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "section": {"@section-type": "subsequent-section", "#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "742."}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Reauthorization; reporting\n\t\t\t\trequirements", "@display-inline": "yes-display-inline"}, "subsection": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall prepare and submit to the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", and the ", "@entity-type": "committee", "#text": "Committee on\n\t\t\t\tHealth, Education, Labor, and Pensions of the Senate", "@entity-id": "SSHR00"}, {"#tail": " a report concerning the\n\t\t\t\tprogress of the ", "@entity-type": "committee", "#text": "Committee on\n\t\t\t\tEnergy and Commerce of the House of Representatives", "@entity-id": "HIF00"}, {"#tail": " in achieving the goals identified\n\t\t\t\tin the letters described in ", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, {"#tail": " toward expediting the generic new animal drug development\n\t\t\t\tprocess and the review of abbreviated applications for generic new animal\n\t\t\t\tdrugs, supplemental abbreviated applications for generic new animal drugs, and\n\t\t\t\tinvestigational submissions for generic new animal drugs during such fiscal\n\t\t\t\tyear.", "@entity-type": "act", "#text": "section 201(b) of the Animal Generic Drug User Fee\n\t\t\t\tAmendments of 2013", "@value": "Animal Generic Drug User Fee Amendments of 2013/s:201/ss:b"}], "#text": "Beginning with fiscal year 2014, not later\n\t\t\t\tthan 120 days after the end of each fiscal year during which fees are collected\n\t\t\t\tunder this part, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(a)"}, "header": {"#tail": "\n              ", "#text": "Performance reports", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idcc2b5fe0841b4a58a399eacfdda009d9", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall prepare and submit to ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and the ", "@entity-type": "committee", "#text": "Committee on Health,\n\t\t\t\tEducation, Labor, and Pensions of the Senate", "@entity-id": "SSHR00"}, {"#tail": " a report on the implementation of the\n\t\t\t\tauthority for such fees during such fiscal year and the use, by the ", "@entity-type": "committee", "#text": "Committee on Energy and\n\t\t\t\tCommerce of the House of Representatives", "@entity-id": "HIF00"}, {"#tail": ", of the fees collected during such fiscal year for which\n\t\t\t\tthe report is made.", "@entity-type": "federal-body", "#text": "Food and\n\t\t\t\tDrug Administration", "@entity-id": "7524"}], "#text": "Beginning with fiscal year 2014, not later\n\t\t\t\tthan 120 days after the end of each fiscal year during which fees are collected\n\t\t\t\tunder this part, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(b)"}, "header": {"#tail": "\n              ", "#text": "Fiscal report", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "id835ab04b07944f3495a0b776958364cf", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall make the reports\n\t\t\t\trequired under subsections (a) and (b) available to the public on the Internet\n\t\t\t\tWeb site of the Food and Drug Administration.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(c)"}, "header": {"#tail": "\n              ", "#text": "Public availability", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "ide8a865f3fe1b4ddcb4bce882749273bc", "@commented": "no"}, {"#tail": "\n          ", "enum": {"#tail": "\n              ", "#text": "(d)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Reauthorization", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall consult\n\t\t\t\twith\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "In developing recommendations to present to\n\t\t\t\tCongress with respect to the goals, and plans for meeting the goals, for the\n\t\t\t\tprocess for the review of abbreviated applications for generic new animal drugs\n\t\t\t\tfor the first 5 fiscal years after fiscal year 2018, and for the\n\t\t\t\treauthorization of this part for such fiscal years, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Consultation", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idac49410f3e04466eb5d4705b029658a1", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "committee", "#text": "Committee on Energy and Commerce of the\n\t\t\t\tHouse of Representatives", "@entity-id": "HIF00"}, "#text": "the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id4424ac037ce048e08c13f9ace54078f0", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "committee", "#text": "Committee on Health, Education, Labor,\n\t\t\t\tand Pensions of the Senate", "@entity-id": "SSHR00"}, "#text": "the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id3c0b326cc82b4f2eb486d437381d908d", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "scientific and academic experts;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id2007e9060e7f4ce0b9906b7dc174a91e", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "veterinary professionals;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idcbae80e7d0434ac3bb6fc50b2419692b", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "representatives of patient and consumer\n\t\t\t\tadvocacy groups; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(E)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id8a94fc1d5b374adaafd894f8aea8ad47", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "the regulated industry.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(F)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "ida454eb7bb12e4255b1ef5fabeb9e6b84", "@commented": "no"}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t\tshall\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Prior to beginning negotiations with the\n\t\t\t\tregulated industry on the reauthorization of this part, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Prior public input", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "id915ae04fbce44fa68d50558bc13be3a5", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "publish a notice in the Federal Register\n\t\t\t\trequesting public input on the reauthorization;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "iddd34e804fc044010a55d22cf279343bb", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "hold a public meeting at which the public\n\t\t\t\tmay present its views on the reauthorization, including specific suggestions\n\t\t\t\tfor changes to the goals referred to in subsection (a);", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "idbdd37c4c28c545cc92470a1b8f5b60ac", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "provide a period of 30 days after the\n\t\t\t\tpublic meeting to obtain written comments from the public suggesting changes to\n\t\t\t\tthis part; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id8023f630ea3b43e5b7f94f0391a2c307", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u2019s Internet Web site.", "@entity-type": "federal-body", "#text": "Food and Drug\n\t\t\t\tAdministration", "@entity-id": "7524"}, "#text": "publish the comments on the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id63c29888c82f4caca110a4dc9f89ad35", "@commented": "no"}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\n\t\t\t\thold discussions with representatives of veterinary, patient, and consumer\n\t\t\t\tadvocacy groups to continue discussions of their views on the reauthorization\n\t\t\t\tand their suggestions for changes to this part as expressed under paragraph\n\t\t\t\t(2).", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Not less frequently than once every 4\n\t\t\t\tmonths during negotiations with the regulated industry, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Periodic consultation", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idd320528a5f7645c38d661673a6a963e9", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "After\n\t\t\t\tnegotiations with the regulated industry, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n                ", "#text": "Public review of\n\t\t\t\trecommendations", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idb6e5f2fa49e94ca7bcaf49911e87812b", "@commented": "no", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "present the recommendations developed under\n\t\t\t\tparagraph (1) to the congressional committees specified in such\n\t\t\t\tparagraph;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id3e2b89a584794471bca05fa2ffd5c086", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "publish such recommendations in the Federal\n\t\t\t\tRegister;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "ida0a1729c8cc34b9dae0c2eaf1094eb5f", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "provide for a period of 30 days for the\n\t\t\t\tpublic to provide written comments on such recommendations;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id8cc0c572ab4d40babe8735eb35f0d0f8", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "hold a meeting at which the public may\n\t\t\t\tpresent its views on such recommendations; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id94f16dea6f284626a20cfc70792d3aa4", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "after consideration of such public views\n\t\t\t\tand comments, revise such recommendations as necessary.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(E)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "ida0afecd1e23a4b2492d2c63e3af311e0", "@commented": "no"}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall transmit to ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " the revised\n\t\t\t\trecommendations under paragraph (4), a summary of the views and comments\n\t\t\t\treceived under such paragraph, and any changes made to the recommendations in\n\t\t\t\tresponse to such views and comments.", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}], "#text": "Not later\n\t\t\t\tthan January 15, 2018, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(5)"}, "header": {"#tail": "\n                ", "#text": "Transmittal of\n\t\t\t\trecommendations", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "ide67e693bd59046f0bba725622f01a5e0", "@commented": "no"}, {"#tail": "\n            ", "@id": "idb6c9d4b8ddaf488fbdc61d48bc0fc4f0", "enum": {"#tail": "\n                ", "#text": "(6)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Minutes of negotiation meetings", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, {"#tail": " shall\n\t\t\t\tmake publicly available, on the Internet Web site of the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", minutes of all negotiation meetings conducted under this\n\t\t\t\tsubsection between the ", "@entity-type": "federal-body", "#text": "Food and Drug\n\t\t\t\tAdministration", "@entity-id": "7524"}, {"#tail": " and the regulated\n\t\t\t\tindustry.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "Before presenting the recommendations\n\t\t\t\tdeveloped under paragraphs (1) through (5) to ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "header": {"#tail": "\n                  ", "#text": "Public availability", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "id8da31d49fa5d4e03acf0fc6e923ea800", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "The minutes described under subparagraph\n\t\t\t\t(A) shall summarize any substantive proposal made by any party to the\n\t\t\t\tnegotiations as well as significant controversies or differences of opinion\n\t\t\t\tduring the negotiations and their\n\t\t\t\tresolution.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n                  ", "#text": "Content", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "ide3d516771ddb4edb9694aa02f70d8dfd", "@commented": "no"}], "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n              ", "@id": "idfc6a959f0e7c4f0e9ae966273a14cbfa", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "id64016AE763B143F8BB332EDA9D3D69A0", "@commented": "no"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "id007B6113BEBB47D8BCF3460EDCDFD939"}, "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "id86BF1F833AFE43B28EDEE90F35A3DA96", "@commented": "no"}, {"@section-type": "subsequent-section", "#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", as in effect on the day before the date\n\t\t\t of enactment of this title, shall continue to be in effect with respect to\n\t\t\t abbreviated applications for a generic new animal drug and supplemental\n\t\t\t abbreviated applications for a generic new animal drug (as defined in such part\n\t\t\t as of such day) that on or after October 1, 2008, but before October 1, 2013,\n\t\t\t were accepted by the ", "@entity-type": "act", "#text": "part 5 of subchapter C of chapter VII of the\n\t\t\t Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:5"}, {"#tail": " for filing with respect to\n\t\t\t assessing and collecting any fee required by such part for a fiscal year prior\n\t\t\t to fiscal year 2014.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "Notwithstanding the\n\t\t\t amendments made by this title, ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n        ", "#text": "204."}, "header": {"#tail": "\n        ", "#text": "Savings\n\t\t\t clause", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "idE3F39FD53D1C45CCAF4D42AE9FAB3054", "@commented": "no"}, {"@section-type": "subsequent-section", "#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", as amended by this\n\t\t\t title, shall be assessed for all abbreviated applications for a generic new\n\t\t\t animal drug and supplemental abbreviated applications for a generic new animal\n\t\t\t drug received on or after October 1, 2013, regardless of the date of enactment\n\t\t\t of this Act.", "@entity-type": "act", "#text": "part 5 of subchapter C of\n\t\t\t chapter VII of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:5"}, "#text": "The amendments made by\n\t\t\t this title shall take effect on October 1, 2013, or the date of enactment of\n\t\t\t this Act, whichever is later, except that fees under ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n        ", "#text": "205."}, "header": {"#tail": "\n        ", "#text": "Effective\n\t\t\t date", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "id0093861360504679B096AF5D36435FAA", "@commented": "no"}, {"@section-type": "subsequent-section", "#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "206."}, "header": {"#tail": "\n\t\t\t\t", "#text": "Sunset dates", "@display-inline": "yes-display-inline"}, "subsection": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " shall cease to be effective October 1,\n\t\t\t 2018.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 741 of the Federal Food, Drug, and\n\t\t\t Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:741", "@proposed": "true"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "\n                21 U.S.C. 379j\u201321", "@value": "usc/21/379j\u201321", "@proposed": "true"}, "@parsable-cite": "usc/21/379j-21", "#text": "\n              ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(a)"}, "header": {"#tail": "\n          ", "#text": "Authorization", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "id7d12783b3b50456b9bcaeb4239a18160", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " shall cease to be effective January 31,\n\t\t\t 2019.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 742 of the Federal Food, Drug, and\n\t\t\t Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:742", "@proposed": "true"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "\n                21 U.S.C. 379j\u201322", "@value": "usc/21/379j\u201322", "@proposed": "true"}, "@parsable-cite": "usc/21/379j-22", "#text": "\n              ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(b)"}, "header": {"#tail": "\n          ", "#text": "Reporting requirements", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "ide4387464b55c450689665d11bd28c6a9", "@commented": "no"}, {"#tail": "\n      ", "enum": {"#tail": "\n          ", "#text": "(c)"}, "header": {"#tail": "\n\t\t\t\t\t", "#text": "Previous sunset provision", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "\n              ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is repealed.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 204 of the Animal Generic Drug User\n\t\t\t Fee Act of 2008", "@value": "Animal Generic Drug User Fee Act of 2008/s:204"}, "@entity-type": "law-citation", "#text": "\n                ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "public-law", "#text": "Public Law 110\u2013316", "@value": "public-law/110/316"}, "@parsable-cite": "pl/110/316", "#text": "\n                ", "@legal-doc": "public-law"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "header": {"#tail": "\n            ", "#text": "In general", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "id560945a3ba304afcbfb7e9fb3fe3f851", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 204", "@value": "Animal Generic Drug User Fee Act of 2008/s:204"}, "#text": "The ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended in the table of contents in section 1, by\n\t\t\t striking the item relating to ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Animal Generic Drug User Fee Act of\n\t\t\t 2008", "@value": "Animal Generic Drug User Fee Act of 2008"}, "@entity-type": "law-citation", "#text": "\n                ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "public-law", "#text": "Public Law 110\u2013316", "@value": "public-law/110/316"}, "@parsable-cite": "pl/110/316", "#text": "\n                ", "@legal-doc": "public-law"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "header": {"#tail": "\n            ", "#text": "Conforming amendment", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "idb437a3f3cd77458aaa8b9fdd29c5c6a7", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "id118d05bc7b3c4d39aef1e2668cd6cbbc", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "id6738992BAF6E4409B631A215FF4D8E5C", "@commented": "no"}], "enum": {"#tail": "\n      ", "#text": "II"}, "#tail": "\n  ", "header": {"#tail": "\n\t\t\t", "#text": "Fees relating to generic animal\n\t\t\t drugs", "@display-inline": "yes-display-inline"}, "#text": "\n      ", "@id": "id887345CBA94A46EFAF59D050D74EF0E8", "@commented": "no"}], "#tail": "\n\t", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": {"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "Animal Drug and Animal Generic Drug\n\t\t\t User Fee Reauthorization Act of 2013", "@value": "Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013", "@proposed": "true"}, "#text": "\n            "}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the\n\t\t\t ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n      ", "@id": "S1", "@commented": "no"}, {"@section-type": "subsequent-section", "#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n\t\t\t", "#text": "Table of contents; references in\n\t\t\t Act", "@display-inline": "yes-display-inline"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "The table of contents of this Act is as\n\t\t\t follows:", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Table of contents", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "toc": {"#tail": "\n\t\t\t", "#text": "\n\t\t\t\t\t", "toc-entry": [{"@idref": "S1", "@level": "section", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "Sec. 1. Short\n\t\t\t\ttitle."}, {"@idref": "id6DDE233C8DD34BA49B288F3202F70B43", "@level": "section", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "Sec. 2. Table of contents; references in Act."}, {"@idref": "idCAB9CAD96B1741ABBCE4EB6FD7B2A456", "@level": "title", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "TITLE I\u2014Fees relating to animal drugs"}, {"@idref": "idF24B38947FC6403FAF022C0E445C8BB9", "@level": "section", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "Sec. 101. Short title; finding."}, {"@idref": "id18C46899033642ECAD36671387E81948", "@level": "section", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "Sec. 102. Definitions."}, {"@idref": "idE57FA6A8996142F597DE8AD3F7810778", "@level": "section", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "Sec. 103. Authority to assess and use animal drug\n\t\t\t\tfees."}, {"@idref": "idF95379A251544E6E81CF9BBCFDFA1C6E", "@level": "section", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "Sec. 104. Reauthorization; reporting requirements."}, {"@idref": "idba28b0f6449e4cf594c392846a403b7d", "@level": "section", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "Sec. 105. Savings clause."}, {"@idref": "idc9d1267aec5c4c19b7d4aa9c166e8eee", "@level": "section", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "Sec. 106. Effective date."}, {"@idref": "id0b82b2aad4a449f1a2d259581c5c328c", "@level": "section", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "Sec. 107. Sunset dates."}, {"@idref": "id887345CBA94A46EFAF59D050D74EF0E8", "@level": "title", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "TITLE II\u2014Fees relating to generic animal drugs"}, {"@idref": "id7BD7ADAD8E32489AACA44A75A67EB6D3", "@level": "section", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "Sec. 201. Short title; finding."}, {"@idref": "id105B4517DF0E45CC895D417541929E33", "@level": "section", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "Sec. 202. Authority to assess and use generic new animal drug\n\t\t\t\tfees."}, {"@idref": "id86BF1F833AFE43B28EDEE90F35A3DA96", "@level": "section", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "Sec. 203. Reauthorization; reporting requirements."}, {"@idref": "idE3F39FD53D1C45CCAF4D42AE9FAB3054", "@level": "section", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "Sec. 204. Savings clause."}, {"@idref": "id0093861360504679B096AF5D36435FAA", "@level": "section", "#tail": "\n\t\t\t\t\t", "@bold": "off", "#text": "Sec. 205. Effective date."}, {"@idref": "id6738992BAF6E4409B631A215FF4D8E5C", "@level": "section", "#tail": "\n\t\t\t\t", "@bold": "off", "#text": "Sec. 206. Sunset dates."}]}, "#text": "\n        ", "@id": "id6563FD38C07040FEB98F43E38C40CD71", "@commented": "no"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "Except as otherwise specified, amendments\n\t\t\t made by this Act to a section or other provision of law are amendments to such\n\t\t\t section or other provision of the ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21\n\t\t\t U.S.C. 301 et seq.", "@value": "usc/21/301/etseq"}], "@entity-type": "law-citation", "#text": "\n            "}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "References in Act", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "idE29AD33021E4498E9F8AC1985ECF307F", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n      ", "@id": "id6DDE233C8DD34BA49B288F3202F70B43", "@commented": "no"}], "@display-enacting-clause": "yes-display-enacting-clause", "#text": "\n\t\t"}, "@public-print": "no", "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": " S622 ENR: Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. Senate"}, "#text": "\n"}, "#text": "\n"}}}